Can a woman with SLE have a healthy pregnancy?

Yes. Many women with systemic lupus erythematosus have successful pregnancies, particularly when: • Lupus is quiet or at low stable activity before conception. • Kidney disease is inactive. • Blood pressure is controlled. • Pregnancy-compatible medicines are continued. • Antiphospholipid, anti-Ro/SSA and anti-La/SSB antibody status is known. • Maternal and fetal surveillance is planned. The individual risk depends on the woman’s disease—not the diagnosis alone. No clinician can guarantee the outcome of a pregnancy.

When is the safest time to become pregnant with lupus?

The safest time is generally when lupus has been clinically quiet or at low stable activity on pregnancy-compatible treatment. Pregnancy may need to be delayed when there is: • Active lupus nephritis. • Severe cardiac, pulmonary, renal or neurological disease. • Pulmonary hypertension. • A recent stroke. • Uncontrolled hypertension. • A pregnancy-incompatible medicine that has not yet been replaced. • An incomplete thrombosis or antibody plan. The preconception review should confirm that the replacement treatment is controlling disease before contraception is stopped. [1,2,5]

Does pregnancy make lupus worse?

Pregnancy does not affect every woman in the same way. Lupus may remain quiet, particularly when disease was controlled before conception and effective treatment continues. Flares can occur during pregnancy or postpartum. They are often mild or moderate, but severe organ flares are possible. Risk is greater when: • Disease was active near conception. • Lupus nephritis is active. • Hydroxychloroquine or another maintenance medicine is stopped. • Infection occurs. • Follow-up is interrupted. New symptoms should be assessed rather than assumed to be either normal pregnancy or lupus.

Can my baby inherit lupus?

SLE is not inherited through one simple gene. A child may inherit some genetic susceptibility to autoimmune disease, but most children born to mothers with SLE do not develop lupus. Anti-Ro/SSA and anti-La/SSB antibodies may cross the placenta and cause neonatal lupus in a small proportion of exposed infants. Neonatal lupus is not the same as inherited lifelong SLE. Most non-cardiac neonatal lupus findings are temporary as maternal antibodies disappear from the baby’s circulation.

How can doctors tell a lupus flare from preeclampsia?

No single test separates every case. The team compares: • Timing in pregnancy. • Pre-pregnancy and early-pregnancy blood pressure. • Baseline kidney function and urine protein. • Urinary sediment. • Complement trend. • Anti-double-stranded DNA trend. • Extra-renal lupus symptoms. • Platelets and liver tests. • Fetal growth and placental findings. • Angiogenic biomarkers where validated and available. Active urinary sediment, falling complement, rising anti-double-stranded DNA and other lupus manifestations may support nephritis. New hypertension after 20 weeks, placental dysfunction, liver or neurological features and a preeclampsia-type angiogenic pattern may support preeclampsia. Both conditions can occur together. [4,5]

Is hydroxychloroquine safe in pregnancy?

Hydroxychloroquine is a central pregnancy-compatible medicine for most women with SLE. It may help maintain disease control, reduce flare risk and reduce the need for higher steroid exposure. SMFM recommends continuing or initiating it during pregnancy for women with SLE other than selected patients with quiescent disease who are not already receiving treatment. For a woman with quiet disease who is not taking hydroxychloroquine, starting it can be discussed with rheumatology through shared decision-making. [1] It should not be stopped automatically because pregnancy has begun.

Should I stop my lupus medicines when I find out that I am pregnant?

Do not stop all medicines automatically. Some lupus medicines are compatible with pregnancy and may be protecting the kidneys, blood, lungs, heart or nervous system. Others require urgent replacement because they are pregnancy incompatible. The safest response is to: • Contact rheumatology and obstetric care promptly. • Confirm every medicine and dose. • Identify the disease controlled by each medicine. • Replace unsafe treatment without leaving lupus unprotected. • Assess current disease activity. Abrupt withdrawal can trigger a flare and create greater maternal and fetal risk.

Which lupus medicines are not used routinely during pregnancy?

Pregnancy-incompatible or generally avoided medicines include: • Mycophenolate. • Methotrexate. • Leflunomide. • Voclosporin because pregnancy evidence is insufficient. • Cyclophosphamide in routine pregnancy care. Cyclophosphamide may be considered only in rare life-threatening or organ-threatening disease when no safer effective alternative exists, usually after the first trimester and through multidisciplinary counselling. An exposure does not mean that every fetus will be affected. It requires urgent specialist review, exact exposure dating, safe disease-treatment substitution and appropriate fetal assessment. [1,2,5]

Will I need low-dose aspirin?

SMFM recommends low-dose aspirin beginning at 12 weeks and continuing until delivery for pregnant patients with SLE to reduce preeclampsia risk. [1] The individual plan should still consider: • Aspirin allergy. • Bleeding. • Platelet count. • Anticoagulation. • Planned procedures. • Another contraindication. • Local obstetric guidance. Low-dose aspirin used for preeclampsia prevention is different from full-dose aspirin used for pain. Do not start, stop or change it without the treating team.

What if antiphospholipid antibodies are positive but I have never had a clot or APS pregnancy complication?

A positive antibody does not automatically mean antiphospholipid syndrome. The team should review: • Which antibody is positive. • Its level. • Whether it is persistent. • Whether lupus anticoagulant is present. • Whether more than one antibody is positive. • The complete thrombosis and pregnancy history. • Additional thrombosis risk factors. For a woman with SLE and antiphospholipid antibodies but no clinical event meeting APS criteria, SMFM and ACR support low-dose aspirin rather than routine heparin for every case. [1,2] Individualisation may be needed for a particularly high-risk antibody profile or additional clinical risks.

How is obstetric antiphospholipid syndrome treated in pregnancy?

For obstetric APS without previous thrombosis, standard treatment generally combines: • Low-dose aspirin. • Prophylactic unfractionated heparin or low-molecular-weight heparin. The diagnosis should be based on the appropriate pregnancy history and persistent laboratory findings. The exact heparin preparation and regimen require a specialist prescription. Treatment reduces risk. It does not guarantee that pregnancy loss, preeclampsia, fetal growth restriction or preterm birth cannot occur. [1,2]

What if I have had a previous blood clot?

A previous venous or arterial thrombosis changes the pregnancy plan. When thrombotic APS is present, therapeutic-dose heparin is generally required during pregnancy, commonly together with low-dose aspirin. The team should review: • Type and site of thrombosis. • Whether it was provoked. • Antiphospholipid-antibody profile. • Recurrence. • Current anticoagulant. • Kidney function. • Weight. • Bleeding history. • Delivery and anaesthetic planning. Do not stop an existing anticoagulant without an immediate specialist replacement plan. [1,2]

What do anti-Ro/SSA and anti-La/SSB antibodies mean for pregnancy?

These antibodies may cross the placenta. They are associated with neonatal lupus, including: • Congenital heart block. • Other fetal or neonatal cardiac disease. • A temporary neonatal rash. • Temporary blood-count abnormalities. • Temporary liver-test abnormalities. They are not measures of how active maternal lupus is. Most antibody-exposed babies are not affected. The pregnancy plan should document the exact antibody, previous affected child, hydroxychloroquine use and fetal-cardiac strategy.

What is the chance of congenital heart block?

For an anti-Ro/SSA-positive woman with no previously affected child, the risk of complete congenital heart block is approximately 1% to 2%. After a previous child with cardiac neonatal lupus, recurrence risk is substantially higher, around 17% in a large registry study. [2,9,10] These are population estimates. They do not predict with certainty what will happen in one pregnancy. Most first at-risk pregnancies do not develop congenital heart block.

Will I need a fetal echocardiogram every week?

Professional recommendations differ. ACR conditionally recommends: • Serial fetal echocardiography less often than weekly from 16–18 through 26 weeks when there has been no previously affected infant. • Weekly fetal echocardiography during that period after a previously affected infant. SMFM recommends that routine serial fetal echocardiograms for PR-interval screening should not be performed outside a clinical-trial setting because improved outcomes have not been proved. [1,2] The plan should explain which framework is being followed and why, considering previous history, local fetal-cardiology expertise and the woman’s preferences.

Can congenital heart block be prevented?

No intervention guarantees prevention. Hydroxychloroquine should generally continue for maternal SLE control. For anti-Ro/SSA-positive women with a previous pregnancy affected by congenital heart block, prospective evidence supports hydroxychloroquine as secondary prevention and showed recurrence lower than the historical rate. [8] Hydroxychloroquine does not eliminate recurrence risk. Routine preventive steroid treatment is not recommended. Any fetal treatment for detected conduction disease remains specialist and evidence-limited.

How will my baby be monitored during pregnancy?

The plan may include: • Early dating ultrasound. • Detailed fetal anatomy. • Serial growth scans. • Amniotic-fluid assessment. • Umbilical-artery Doppler when indicated. • Antenatal fetal testing. • A fetal-cardiac plan for anti-Ro/SSA or anti-La/SSB antibodies. • Additional surveillance for hypertension, APS or fetal growth restriction. SMFM recommends serial growth scans and antenatal testing in SLE because fetal growth restriction and stillbirth risk are increased. [1] The schedule should be individualised rather than copied from another pregnancy.

Does lupus mean that I will need early delivery or a caesarean birth?

No. SLE alone does not require preterm birth or caesarean delivery. A stable woman with quiet disease, controlled blood pressure, stable kidney function and reassuring fetal growth may continue to a planned term birth. Earlier delivery may be required for: • Severe preeclampsia. • Maternal organ deterioration. • Uncontrolled hypertension. • Fetal growth restriction with concerning surveillance. • Thrombosis or serious bleeding. • Fetal compromise. • Another obstetric indication. Vaginal birth is often appropriate. The birth plan should respond to the actual maternal and fetal condition.

Can I have an epidural if I am taking heparin?

Possibly. Epidural or spinal analgesia depends on: • The heparin preparation. • Whether the dose is prophylactic or therapeutic. • The time since the last dose. • Kidney function. • Platelet count and trend. • Bleeding risk. • Anaesthetic guidance. • Urgency of birth. The same safety issue applies when an epidural catheter is removed and anticoagulation is restarted. A written plan should be made before labour. Do not omit heparin doses independently to try to secure an epidural.

Can I breastfeed while taking lupus medicines?

Breastfeeding is often possible. Medicines generally considered compatible include: • Hydroxychloroquine. • Prednisone or prednisolone. • Azathioprine. • Tacrolimus. • Ciclosporin. • Unfractionated heparin. • Low-molecular-weight heparin. • Warfarin. Biologic treatment requires drug-specific review. Medicines generally avoided during breastfeeding include mycophenolate, cyclophosphamide and leflunomide; methotrexate is also generally avoided. [2,6] Maternal disease control takes priority when organ-threatening lupus requires treatment that is not compatible with breastfeeding.

Which symptoms require urgent assessment during pregnancy or after birth?

Seek urgent medical or maternity assessment for: • Reduced or absent fetal movements. • Vaginal bleeding or fluid leakage. • Severe headache or visual disturbance. • Upper-abdominal or epigastric pain. • Severe or persistent high blood pressure. • Chest pain. • Sudden or significant breathlessness. • One-sided leg swelling. • Fainting. • Seizure. • New weakness, speech difficulty or another neurological symptom. • Fever. • Markedly reduced urine output. • Heavy postpartum bleeding. • A slow or concerning newborn heart rate. • Feeling seriously unwell. • Thoughts of self-harm or harming the baby. SLE should lower the threshold for organised assessment. It should not lead to every symptom being attributed automatically to lupus.

SLE in Pregnancy

When Lupus Activity, Placental Risk and Pregnancy Must Be Managed Together

Q: Does a positive ANA mean that I have lupus?

No. A positive antinuclear antibody test can occur in: • SLE. • Another autoimmune condition. • Infection. • Medication-related states. • Some healthy people. SLE is diagnosed from the complete clinical and immunological picture. A positive ANA alone does not prove lupus. A negative or changing individual test should also not be used by itself to dismiss a well-established diagnosis.

Pregnancy is possible for many women living with systemic lupus erythematosus.

The safest pregnancy usually begins before conception—with the disease pattern understood, activity controlled, medicines reviewed and the important antibodies documented.

SLE is not one uniform illness.

One woman may have mainly skin and joint symptoms.

Another may have lupus nephritis, low platelets, previous thrombosis, neurological disease, pulmonary hypertension or major cardiac involvement.

Two women with the same diagnosis may therefore enter pregnancy with very different maternal and fetal risks.

The pregnancy plan must answer more than one question:

Is lupus currently active?
Which organs have ever been involved?
Is kidney disease active, inactive or permanently damaged?
Are antiphospholipid antibodies present?
Has the woman ever had thrombosis or pregnancy morbidity meeting criteria for antiphospholipid syndrome?
Are anti-Ro/SSA or anti-La/SSB antibodies present?
Which medicines are protecting disease control?
Which medicines are compatible with pregnancy?
Is maternal blood pressure normal?
What baseline laboratory values will help distinguish a later flare from preeclampsia?
What surveillance will protect both mother and baby?

Lupus does not automatically make pregnancy unsafe.

Active disease, major organ involvement, uncontrolled hypertension, unsafe medication exposure or incomplete risk assessment can make it substantially more complicated.

My approach begins with three principles:

Enter pregnancy with lupus as quiet and stable as possible.
Continue effective pregnancy-compatible treatment rather than stopping protection out of fear.
Separate lupus activity, placental disease and normal pregnancy changes before making major decisions.

No doctor can guarantee the outcome of a pregnancy.

Expert care can do something more useful:

Define the woman’s individual lupus pattern.
Identify organ damage and active inflammation separately.
Review lupus nephritis before it is confused with preeclampsia.
Test the antibodies that change fetal and thrombosis planning.
Protect disease control with appropriate medicines.
Plan maternal and fetal surveillance.
Recognise deterioration early.
Coordinate obstetric, rheumatology, renal, cardiac or other specialist care when required.
Prepare for birth and the postpartum period, when disease activity and thrombosis risk may change.

Schedule an SLE Pregnancy Consultation Review Your Lupus, Antibodies and Medicines

Establish the Baseline

First Establish the Lupus Baseline

Pregnancy should not be managed from the word lupus alone.

The first task is to establish exactly what the diagnosis has meant for this woman.

Confirm the Diagnosis and Its Evidence

SLE is diagnosed from the complete clinical and immunological picture.

The review may include:

The original symptoms.
Examination findings.
Antinuclear antibody testing.
Anti-double-stranded DNA antibodies.
Anti-Smith antibodies.
Complement levels.
Blood-count abnormalities.
Urine findings.
Kidney biopsy when performed.
Skin biopsy when performed.
Neurological, cardiac, pulmonary or vascular involvement.
The rheumatologist’s diagnostic assessment.
Previous classification criteria used in the record.

A positive antinuclear antibody test alone does not establish SLE.

Many people with a positive ANA do not have lupus.

The diagnosis should not be created or dismissed from one laboratory result.

SLE Is a Multisystem Disease

Lupus may involve:

Skin.
Joints.
Kidneys.
Blood cells.
Nervous system.
Heart.
Lungs.
Blood vessels.
Eyes.
Other organs.

The pregnancy plan depends on which systems are involved now and which have been involved previously.

A history of serious organ disease remains relevant even during remission.

Establish Current Disease Activity

Current activity should be assessed before conception or as early as possible in pregnancy.

The review may include:

New rash.
Mouth or nasal ulcers.
Joint swelling.
Serositis.
Fever not explained by infection.
Neurological symptoms.
Blood-count change.
Rising proteinuria.
Active urinary sediment.
Kidney-function change.
Anti-double-stranded DNA trend.
Complement trend.
The woman’s established flare pattern.
A validated lupus disease-activity measure when used by the treating team.

Symptoms should be compared with the woman’s own baseline.

One abnormal test does not define activity in isolation.

Separate Active Disease From Permanent Organ Damage

A woman may have:

Active inflammation.
Previous organ damage.
Both.
Neither.

Examples of previous damage may include:

Chronic kidney impairment after earlier nephritis.
Residual proteinuria.
Hypertension.
Previous stroke.
Valvular disease.
Pulmonary damage.
Avascular necrosis after steroid exposure.
Persistent neuropathy.

Permanent damage may increase pregnancy risk even when lupus is not currently flaring.

It should not be treated automatically as active inflammation.

Lupus Nephritis Requires Its Own Baseline

Kidney involvement is one of the most important determinants of pregnancy risk.

I review:

Previous nephritis class when biopsy was performed.
Date and severity of the last renal flare.
Current creatinine.
Estimated kidney function.
Urine protein.
Urine protein-to-creatinine ratio or another quantitative measure.
Urinary sediment.
Blood pressure.
Complement.
Anti-double-stranded DNA trend.
Current and previous renal medicines.
Whether remission is complete, partial or uncertain.
Permanent kidney damage.
Previous dialysis or kidney transplantation.
Nephrologist and rheumatologist assessments.

Active lupus nephritis is associated with greater maternal and fetal risk and is one of the situations in which pregnancy may be strongly discouraged until disease control improves. ^[1,5]

Blood Pressure Must Be Documented Before It Changes

Baseline blood pressure helps later interpretation.

The review should include:

Chronic hypertension.
Usual pre-pregnancy readings.
Current readings.
Antihypertensive medicines.
Previous gestational hypertension or preeclampsia.
Kidney disease.
Home blood-pressure technique when used.
Symptoms that require urgent assessment.

Hypertension may reflect:

Chronic disease.
Kidney involvement.
Steroid effects.
Pregnancy-related hypertension.
Preeclampsia.
More than one process.

The baseline should be established before late-pregnancy changes create diagnostic uncertainty.

Establish the Blood-Count Baseline

SLE may affect:

Haemoglobin.
White blood cells.
Lymphocytes.
Platelets.

Pregnancy also changes blood volume and laboratory reference ranges.

The record should establish:

The woman’s usual haemoglobin.
Previous autoimmune haemolysis.
Baseline white-cell and lymphocyte counts.
Previous immune thrombocytopenia.
Current platelet count.
Medication-related abnormalities.
Other causes such as iron, vitamin B12 or folate deficiency.

A low platelet count later in pregnancy may have several explanations.

Knowing the baseline prevents one number from being interpreted without context.

Review Cardiac and Pulmonary Involvement

The history should identify:

Pericarditis.
Myocarditis.
Cardiomyopathy.
Valvular disease.
Libman–Sacks endocarditis.
Coronary disease.
Pulmonary hypertension.
Interstitial lung disease.
Previous pulmonary embolism.
Pleural disease.
Reduced exercise tolerance.
Unexplained breathlessness.
Previous echocardiography or pulmonary testing.

Severe cardiac or pulmonary disease can make pregnancy dangerous.

Pulmonary hypertension is a particularly high-risk condition and requires specialist counselling. ^[1]

Review Neurological and Vascular Disease

The history should include:

Seizures.
Stroke.
Transient ischaemic attack.
Cerebral venous thrombosis.
Psychosis attributed to lupus.
Peripheral neuropathy.
Myelitis.
Severe headaches with a previous lupus diagnosis.
Vasculitis.
Previous arterial or venous thrombosis.

A recent stroke, severe neurological disease or major vascular disease may substantially alter pregnancy counselling and management. ^[1]

Review Previous Thrombosis

I ask about:

Deep-vein thrombosis.
Pulmonary embolism.
Stroke.
Transient ischaemic attack.
Retinal thrombosis.
Unusual-site venous thrombosis.
Arterial thrombosis.
Catheter-associated thrombosis.
Provoking factors.
Anticoagulant treatment.
Recurrence.
Antiphospholipid-antibody results at the time.

Previous thrombosis may indicate:

Antiphospholipid syndrome.
Another thrombophilia.
A provoked event.
More than one risk factor.

The diagnosis changes the pregnancy anticoagulation plan.

Test the Antibodies That Change Pregnancy Care

The pregnancy-relevant antibody review includes:

Lupus anticoagulant.
Anticardiolipin antibodies.
Anti-beta-2 glycoprotein I antibodies.
Anti-Ro/SSA antibodies.
Anti-La/SSB antibodies.
Anti-double-stranded DNA antibodies.
Complement levels.

These tests answer different questions.

Antiphospholipid antibodies influence thrombosis and placental-risk planning.

Anti-Ro/SSA and anti-La/SSB antibodies influence counselling about neonatal lupus and fetal cardiac risk.

Anti-double-stranded DNA and complement trends may help assess lupus activity.

One positive antibody should not be interpreted as though it answers all three questions.

Antiphospholipid Antibodies Are Not Automatically APS

A woman may have:

Negative antiphospholipid antibodies.
One positive result.
Persistent antibodies without clinical events.
Obstetric antiphospholipid syndrome.
Thrombotic antiphospholipid syndrome.
Both obstetric and thrombotic APS.

The diagnosis of APS requires the appropriate clinical and laboratory framework.

A positive antibody alone does not automatically mean that the woman has APS.

It still may change preventive planning in SLE. ^[1,2]

Anti-Ro/SSA and Anti-La/SSB Require Specific Counselling

These antibodies may cross the placenta.

They are associated with neonatal lupus manifestations, including a small risk of congenital heart block.

The assessment should document:

Which antibody is present.
Previous affected child.
Previous fetal or neonatal heart block.
Previous neonatal lupus rash or blood-count abnormality.
Current hydroxychloroquine use.
Rheumatology and fetal-medicine plans.

The detailed fetal-heart discussion and the differences between professional recommendations will be addressed later on this page.

Review Every Medicine Before Conception or Immediately in Pregnancy

The medication record should include:

Hydroxychloroquine.
Glucocorticoids.
Azathioprine.
Tacrolimus or ciclosporin.
Belimumab or another biologic.
Mycophenolate.
Methotrexate.
Cyclophosphamide.
Voclosporin.
Nonsteroidal anti-inflammatory drugs.
Aspirin.
Anticoagulants.
Antihypertensive medicines.
Statins.
Supplements.
Herbal or traditional preparations.

For each medicine, establish:

Exact name.
Dose.
Indication.
Duration.
Disease controlled by it.
Pregnancy compatibility.
Breastfeeding compatibility.
Consequence of stopping it.
Whether substitution is required.
Who is supervising the change.

A medication list without the reason for each treatment is incomplete.

Previous Steroid Exposure Matters

The review should document:

Current dose.
Usual maintenance dose.
Recent high-dose treatment.
Previous intravenous steroid pulses.
Duration of therapy.
Diabetes.
Hypertension.
Osteoporosis.
Fracture or avascular necrosis.
Infection.
Eye complications.
Adrenal-suppression concerns.

Steroids may be necessary for active disease.

The aim is not to deny treatment.

It is to use the lowest effective exposure while protecting maternal organ function.

Review Infection and Vaccination History

SLE and immunosuppressive treatment may alter infection risk.

The review may include:

Previous serious infections.
Tuberculosis risk.
Hepatitis status.
Varicella immunity.
Vaccination history.
Current immunosuppression.
Recent fever or infection.
Planned travel.
Exposure risks.

Vaccination decisions depend on:

Vaccine type.
Gestational timing.
Immunosuppressive treatment.
Maternal risk.
Current recommendations.

Live vaccines are generally avoided during pregnancy.

Routine pregnancy vaccines and other indicated non-live vaccines should be discussed with the clinical team.

Review Fertility and Previous Treatment

Fertility may be affected by:

Age.
Ovarian reserve.
Previous cyclophosphamide exposure.
Active disease.
Kidney disease.
Medication.
Endometriosis or another gynaecological condition.
Male-factor infertility.
Previous fertility treatment.

The history should include:

Menstrual pattern.
Previous pregnancies.
Time trying to conceive.
Ovarian-reserve testing when performed.
Fertility preservation.
Previous assisted reproduction.
Disease activity during fertility treatment.

SLE does not automatically cause infertility.

Previous gonadotoxic treatment or another reproductive condition may be relevant.

Create the Baseline That Will Be Used Later

Before or early in pregnancy, the team should document:

Lupus manifestations.
Current activity.
Previous severe organ disease.
Current medicines.
Blood pressure.
Full blood count.
Kidney function.
Quantified urine protein.
Urinary sediment.
Liver tests when clinically relevant.
Anti-double-stranded DNA antibodies.
Complement.
Antiphospholipid-antibody status.
Anti-Ro/SSA and anti-La/SSB status.
Cardiac, pulmonary or neurological investigations when required.
Previous pregnancy outcomes.
Current obstetric dating.

A good lupus baseline is not paperwork. It is the comparison point that may later separate normal pregnancy, lupus flare, kidney disease and preeclampsia.

Low Disease Activity

Pregnancy Should Begin in Low Disease Activity

The safest time to conceive is generally when SLE is clinically quiet or at low stable activity on pregnancy-compatible treatment.

This principle is supported across rheumatology and maternal–fetal medicine guidance because active disease at conception is associated with greater maternal and fetal risk. ^[1,2,3]

Why Disease Activity at Conception Matters

Active lupus may increase the risk of:

Flare during pregnancy.
Lupus nephritis.
Hypertension.
Preeclampsia.
Thrombosis.
Fetal growth restriction.
Preterm birth.
Pregnancy loss.
Maternal organ deterioration.
More intensive medication exposure during pregnancy.

The degree of risk depends on:

Which organ is active.
Severity.
Duration.
Response to treatment.
Kidney function.
Blood pressure.
Antibody profile.
Other maternal conditions.

A skin or joint flare and active nephritis do not carry the same pregnancy implications.

Low Activity Does Not Mean No Care Is Needed

A woman in remission may still have:

Previous nephritis.
Chronic hypertension.
Permanent kidney damage.
Antiphospholipid antibodies.
Anti-Ro/SSA or anti-La/SSB antibodies.
Previous thrombosis.
Previous fetal growth restriction or preeclampsia.
Medication requirements.
Postpartum flare risk.

Disease control lowers risk.

It does not remove the need for specialist pregnancy planning.

Active Lupus Nephritis Is a Major Warning

Pregnancy is generally discouraged while nephritis is active because of the risk of:

Maternal renal deterioration.
Severe hypertension.
Preeclampsia.
Thrombosis.
Fetal growth restriction.
Preterm birth.
Pregnancy loss.
Difficulty distinguishing renal flare from preeclampsia.
Need for medicines that may not be pregnancy compatible.

The priority is to control kidney inflammation and establish an effective pregnancy-compatible maintenance plan before conception when possible. ^[1,5]

Severe Maternal Disease May Make Pregnancy Unsafe

SMFM recommends that pregnancy generally be discouraged when severe maternal risk is present, including:

Active nephritis.
Severe pulmonary disease.
Severe cardiac disease.
Severe renal disease.
Severe neurological disease.
Recent stroke.
Pulmonary hypertension. [1]

This is not a judgement about the woman’s desire for pregnancy.

It is counselling about the possibility that pregnancy may threaten organ function or life.

The discussion may include:

Treatment and reassessment.
Delaying conception.
Fertility preservation.
Contraception.
Assisted reproduction.
Use of a gestational carrier where lawful and acceptable.
Adoption.
The woman’s values and informed decisions.

Medication Transition Must Happen Before Disease Protection Is Removed

Some medicines require discontinuation before conception.

Others should be continued because stopping them may trigger a flare.

The transition should answer:

Which medicine is incompatible with pregnancy?
What will replace it?
Has the replacement had time to work?
Is disease still controlled?
Has the appropriate washout interval been completed?
Is contraception required during transition?
Has kidney, blood-count or liver monitoring been repeated?
Who will respond if disease activity returns?

Stopping an effective medicine without a replacement is not preconception care.

It is removal of disease protection.

Hydroxychloroquine Should Not Be Stopped Automatically

Hydroxychloroquine is a central pregnancy-compatible treatment for many women with SLE.

SMFM recommends that women with SLE other than those with quiescent disease continue or initiate hydroxychloroquine during pregnancy.

For a woman with quiescent disease who is not already taking it, initiation can be considered through shared decision-making with rheumatology. ^[1]

The detailed medication section later on this page will explain:

Benefits.
Safety.
Eye monitoring.
Adherence.
Situations requiring individual review.

An Unplanned Pregnancy Requires Rapid Review—not Panic

When pregnancy occurs before planned counselling:

Do not stop all medicines automatically.
Contact rheumatology and obstetric care promptly.
Confirm gestational age.
Review every medicine.
Identify any time-sensitive exposure.
Assess disease activity.
Check kidney function and urine protein.
Measure blood pressure.
Test pregnancy-relevant antibodies if not documented.
Replace unsafe treatment safely.
Discuss maternal and fetal risks honestly.

Abrupt withdrawal of disease-controlling treatment may create more harm than continued exposure to a pregnancy-compatible medicine.

The response should be organised and time-sensitive.

Contraception Is Part of Safer Pregnancy Planning

Effective contraception may be appropriate while:

Lupus is active.
A pregnancy-incompatible medicine is being used.
A medication transition is incomplete.
Severe organ disease is being assessed.
Blood pressure is uncontrolled.
Anticoagulation planning is unresolved.
The woman does not currently desire pregnancy.

The choice depends on:

Antiphospholipid antibodies.
Thrombosis history.
Disease activity.
Medication.
Blood pressure.
Bleeding pattern.
Personal preference.

Estrogen-containing contraception may be unsuitable for some women with antiphospholipid antibodies or thrombosis risk. ^[2]

Fertility Treatment Requires the Same Disease-Control Principles

Assisted reproduction may be possible when:

Disease is stable.
Medicines are pregnancy compatible.
Thrombosis risk is assessed.
Antiphospholipid-antibody status is known.
Ovarian-stimulation and anticoagulation plans are coordinated.
Maternal organ function is adequate.

The stimulation plan should not proceed as though SLE is separate from fertility treatment.

Rheumatology, reproductive medicine and maternal–fetal medicine may need to plan together.

Preconception Review Is Multidisciplinary Care

The ideal team may include:

Maternal–fetal medicine.
Rheumatology.
Nephrology.
Cardiology.
Pulmonary-hypertension specialists.
Neurology.
Haematology.
Reproductive medicine.
Anaesthesia.
Other specialists according to organ involvement.

Not every woman requires every specialist.

The team should reflect her actual lupus pattern.

Shared Decision-Making Must Include a Medical Recommendation

The woman should understand:

Her current disease activity.
Which organs increase risk.
Whether conception should be delayed.
Which medicines should continue.
Which medicines require substitution.
Antibody-related risks.
Maternal risks.
Fetal risks.
Uncertainty.
Alternatives.
The surveillance burden.
The postpartum plan.

Shared decision-making does not mean that the clinician avoids giving a recommendation.

It means that the recommendation is explained and the woman’s values are respected.

The safest lupus pregnancy is not created by stopping treatment. It is created by entering pregnancy with inflammation controlled and protection deliberately maintained.

Pregnancy & SLE

How Pregnancy Can Affect SLE

Pregnancy changes the immune, vascular, hormonal and metabolic environment.

These changes can influence lupus activity.

The effect is not identical in every woman.

Lupus May Remain Quiet

Many women with well-controlled SLE enter pregnancy and remain clinically stable.

This is more likely when:

Disease activity is low before conception.
Hydroxychloroquine and other appropriate medicines are continued.
Kidney disease is inactive.
Blood pressure is controlled.
Follow-up is regular.
New symptoms are assessed promptly.

A stable pregnancy is possible.

It should not be confused with a pregnancy that needs no surveillance.

Flares Can Occur

Lupus flares during pregnancy are often mild or moderate.

They may involve:

Skin.
Joints.
Blood counts.
Serosal membranes.
Kidneys.
Other organs.

Severe flares are less common but can threaten maternal organ function and pregnancy.

The risk is higher when disease was active near conception or treatment is interrupted. ^[1,2,3]

Pregnancy Symptoms Can Resemble Lupus

Normal pregnancy may cause:

Fatigue.
Mild breathlessness.
Oedema.
Hair changes.
Musculoskeletal discomfort.
Increased heart rate.
Mild anaemia.
Changes in laboratory values.

These symptoms should not automatically be labelled as a lupus flare.

They also should not be dismissed when the woman feels significantly different from her usual pregnancy baseline.

Lupus Symptoms Can Be Mistaken for Normal Pregnancy

Possible flare manifestations may include:

New inflammatory joint swelling.
New lupus rash.
Persistent mouth or nasal ulcers.
Pleuritic chest pain.
Pericardial pain.
Unexplained fever.
Marked blood-count change.
Rising proteinuria.
Active urinary sediment.
Kidney-function deterioration.
Neurological symptoms.
A clear recurrence of the woman’s established flare pattern.

The interpretation requires clinical assessment—not symptom counting from a website.

Infection Must Be Excluded

Fever, fatigue, blood-count change and organ dysfunction may reflect:

Lupus flare.
Infection.
Medication adverse effects.
Pregnancy complications.
More than one process.

Immunosuppression can alter the presentation of infection.

Increasing immunosuppression without considering infection may be dangerous.

Delaying treatment of a true lupus flare can also be dangerous.

The distinction may require cultures, imaging, laboratory trends and specialist review.

Kidney Changes Require Careful Interpretation

Pregnancy may increase:

Renal blood flow.
Glomerular filtration.
Urinary protein excretion.
The diagnostic complexity of kidney findings.

New or worsening proteinuria may reflect:

Lupus nephritis.
Preeclampsia.
Chronic kidney disease.
Urinary infection.
Another renal disorder.
More than one condition.

The baseline creatinine, urine protein, urinary sediment, complement, anti-double-stranded DNA trend and blood pressure become essential.

Complement Levels Change During Pregnancy

Complement proteins may rise during normal pregnancy.

A value that remains inside the laboratory reference range may still represent a meaningful fall from the woman’s pregnancy baseline.

Complement should therefore be interpreted as a trend.

A low or falling complement level may support lupus activity.

It does not diagnose a flare alone.

Anti-Double-Stranded DNA Is a Trend—not a Stand-Alone Diagnosis

Rising anti-double-stranded DNA antibodies may support active lupus, particularly when they change alongside:

Symptoms.
Complement.
Urine findings.
Blood counts.
Kidney function.
Other objective evidence.

Some women have persistently elevated antibodies without a clinical flare.

Treatment should not be escalated solely to normalise one antibody value.

Blood Counts May Change for Several Reasons

Anaemia, low platelets or low white cells may reflect:

SLE.
Medication.
Iron, folate or vitamin B12 deficiency.
Infection.
Preeclampsia or HELLP syndrome.
Haemolysis.
Pregnancy-related dilution.
Bleeding.
Another haematological condition.

The interpretation should use:

Baseline values.
Blood film.
Reticulocytes.
Haemolysis testing.
Iron and vitamin assessment.
Liver tests.
Blood pressure.
Clinical context.

Joint and Skin Symptoms Need Proportionate Treatment

Mild joint or skin activity still matters because:

Pain can reduce mobility and sleep.
Reduced intake may worsen nutrition.
Uncontrolled inflammation may progress.
Stopping medication may allow broader disease activity.

Treatment should remain pregnancy compatible.

The aim is not to tolerate avoidable disease simply because the pregnancy is continuing.

Cardiac or Pulmonary Symptoms Require Urgent Assessment

Chest pain, breathlessness, fainting or reduced exercise tolerance may reflect:

Normal pregnancy.
Anaemia.
Infection.
Pulmonary embolism.
Pulmonary hypertension.
Pericarditis.
Myocarditis.
Cardiomyopathy.
Preeclampsia.
Another emergency.

These symptoms should not be diagnosed remotely as “just lupus.”

Neurological Symptoms Require a Broad Differential

Severe headache, visual disturbance, seizure, confusion, focal weakness or altered behaviour may reflect:

Neuropsychiatric lupus.
Preeclampsia or eclampsia.
Stroke.
Thrombosis.
Infection.
Medication effect.
Migraine.
Another neurological disorder.

Urgent maternity and neurological assessment may be required.

Antiphospholipid Antibodies Can Change Pregnancy Risk Without Causing a Lupus Flare

Placental complications or thrombosis may occur through antiphospholipid-antibody mechanisms rather than active inflammatory lupus.

The woman may have:

Stable lupus.
Normal complement.
No new inflammatory symptoms.
A placenta-related complication.

Disease activity and antibody-mediated risk should not be treated as the same process.

The Postpartum Period Requires Planning

After birth, changes in:

Hormones.
Sleep.
Medication.
Infection exposure.
Blood volume.
Thrombosis risk.
Breastfeeding.
Care responsibilities.

may affect maternal health.

Lupus activity can increase postpartum.

The plan should be written before discharge and should include:

Rheumatology follow-up.
Medication continuation.
Blood-pressure review.
Kidney and urine reassessment.
Thrombosis prevention when indicated.
Contraception.
Symptoms requiring urgent care.

Symptoms That Require Prompt Assessment

Seek prompt medical or maternity assessment for:

Reduced fetal movements.
Vaginal bleeding.
Fluid leakage.
Severe headache.
Visual disturbance.
Upper-abdominal pain.
Chest pain.
Significant breathlessness.
Fainting.
One-sided leg swelling.
Seizure.
New weakness or neurological symptoms.
Fever.
Markedly reduced urine output.
Rapid swelling with hypertension symptoms.
A clear severe lupus flare.
Feeling seriously unwell.

The presence of SLE should lower the threshold for organised assessment.

It should not lead to every symptom being attributed automatically to lupus.

Pregnancy can change lupus, and lupus can change pregnancy. Safe care depends on recognising which process is active before treatment or delivery decisions are made.

The next part will reconstruct the complete lupus, kidney, antibody, medication and pregnancy history; map the investigations; and explain the difficult distinction between lupus flare, lupus nephritis and preeclampsia.

Reconstructing the Story

A safe lupus pregnancy plan begins with a timeline.

The consultation should establish:

When SLE was diagnosed.
Which features supported the diagnosis.
Which organs have ever been involved.
Whether disease is currently quiet, uncertain or active.
When the last flare occurred.
Whether kidney disease has ever been present.
Which antibodies are documented.
Which medicines are controlling the disease.
Whether thrombosis or pregnancy morbidity has occurred.
What changed before conception and after pregnancy began.

The aim is not to collect every historical detail equally.

It is to identify the information that changes maternal, placental, fetal and medication planning.

Reconstruct the Diagnostic Timeline

I review:

Age at first symptoms.
Age at diagnosis.
Original clinical manifestations.
Original antibody results.
Whether classification criteria were met.
Whether another autoimmune diagnosis was considered.
Whether SLE developed gradually or began with severe organ disease.
Which specialist confirmed the diagnosis.
Whether the diagnosis has ever been questioned.
Whether new manifestations developed later.

A patient may carry the label lupus for years without a clear record of how it was established.

Another may have biopsy-proven nephritis with limited extra-renal symptoms.

The pregnancy plan should reflect the documented disease—not assumptions created by the label.

Reconstruct the Flare Pattern

I ask:

What does a typical flare feel like for this woman?
Which symptoms usually appear first?
Which laboratory values change?
Which organs have flared?
How quickly have previous flares progressed?
Which treatments have worked?
Which treatments have failed?
Has hospital admission been required?
Has intensive care ever been required?
Did previous flares follow infection, medication withdrawal, pregnancy or the postpartum period?
When was the last flare?
How long has disease been stable?

A woman’s established flare pattern can be clinically valuable.

It does not replace objective assessment when pregnancy creates a new symptom pattern.

Reconstruct Lupus Nephritis

For every renal episode, I review:

Date.
Pregnancy status at the time.
Symptoms.
Blood pressure.
Creatinine.
Quantified proteinuria.
Urinary sediment.
Complement.
Anti-double-stranded DNA antibodies.
Kidney biopsy class and activity–chronicity findings when available.
Induction treatment.
Maintenance treatment.
Response.
Relapse.
Residual proteinuria.
Permanent kidney impairment.
Dialysis.
Kidney transplantation.

The current pregnancy should not be labelled “no nephritis” merely because creatinine is normal.

Previous biopsy-proven nephritis remains relevant even during remission.

Establish the Pre-Pregnancy Renal Baseline

The most useful comparison may be the last stable period before conception.

I review:

Creatinine.
Estimated kidney function.
Urine protein-to-creatinine ratio or another quantitative measure.
Urinalysis.
Urinary sediment.
Blood pressure.
Serum albumin.
Complement.
Anti-double-stranded DNA trend.
Current renal medicines.
Nephrology assessment.

Residual proteinuria from old kidney damage may continue during a clinically quiet pregnancy.

Without the baseline, it can later be mistaken for new nephritis or preeclampsia.

Reconstruct the Current Pregnancy Timeline

I review:

Last menstrual period.
Cycle regularity.
Ovulation or embryo-transfer date when known.
Earliest ultrasound.
Current estimated due date.
When pregnancy was recognised.
Disease activity at conception.
Medicines taken during the earliest weeks.
Medicines stopped or changed.
Blood-pressure trend.
Kidney and urine results.
Lupus symptoms.
Infection.
Bleeding.
Fetal movements when relevant.
Every hospital or emergency assessment.
Current obstetric concerns.

The timeline should identify whether a change began:

Before conception.
In early pregnancy.
After 20 weeks.
Around a medication change.
After infection.
Alongside hypertension.
Alongside fetal-growth or placental concerns.

Review Every Pregnancy and Its Outcome

For each previous pregnancy, I ask about:

Time to conception.
Early pregnancy loss.
Gestational age at loss.
Fetal heartbeat before loss.
Recurrent loss.
Fetal death.
Preeclampsia.
Fetal growth restriction.
Placental insufficiency.
Preterm birth.
Thrombosis.
Lupus flare.
Lupus nephritis.
Antibody status.
Aspirin or heparin use.
Induction.
Caesarean birth.
Neonatal lupus.
Congenital heart block.
Neonatal-unit admission.
Placental histology.
Postpartum flare.

The exact obstetric history may determine whether antiphospholipid-syndrome criteria are met.

The words “miscarriage” or “placental problem” are not specific enough for that decision.

Reconstruct Antiphospholipid-Antibody Testing

For each test, I review:

Lupus anticoagulant.
Anticardiolipin IgG and IgM.
Anti-beta-2 glycoprotein I IgG and IgM.
Date.
Laboratory.
Value and reference range.
Whether the result was low, medium or high.
Whether positivity was persistent.
Whether repeat testing occurred at the required interval.
Whether anticoagulation affected lupus-anticoagulant interpretation.
Clinical event at the time.
Previous APS diagnosis.

A single weak positive result should not be rewritten as definite APS.

A previous thrombotic event should not be dismissed because the current antibody test is negative.

The complete history and laboratory chronology matter.

Reconstruct Anti-Ro/SSA and Anti-La/SSB History

I review:

Which antibody is positive.
Date tested.
Whether results have been repeated.
Previous fetal-heart surveillance.
Previous congenital heart block.
Previous neonatal lupus rash.
Previous neonatal blood-count or liver abnormality.
Current hydroxychloroquine use.
Maternal Sjögren’s-syndrome features.
Previous counselling.

A previous affected child changes recurrence counselling and specialist planning.

The detailed anti-Ro/SSA and anti-La/SSB section will follow later.

Review Thrombosis in Detail

For each event, establish:

Arterial or venous.
Exact site.
Date.
Provoked or unprovoked.
Pregnancy or postpartum association.
Estrogen exposure.
Surgery, immobility or infection.
Antiphospholipid-antibody status.
Other thrombophilia testing.
Anticoagulant used.
Duration of treatment.
Recurrence.
Bleeding complications.
Current anticoagulation.

A previous pulmonary embolism and an isolated low-positive anticardiolipin result do not create the same plan as obstetric APS without thrombosis.

The intensity and duration of anticoagulation must follow the actual diagnosis.

Review Every Current and Recent Medicine

For each medicine, document:

Generic name.
Brand name when relevant.
Dose.
Frequency.
Route.
Indication.
Start date.
Stop date.
Who prescribed it.
Disease controlled by it.
Pregnancy compatibility.
Breastfeeding compatibility.
Previous adverse effects.
Adherence.
Missed doses.
Whether supply or cost has interrupted treatment.

I specifically ask about:

Hydroxychloroquine.
Prednisone or prednisolone.
Methylprednisolone.
Azathioprine.
Tacrolimus.
Ciclosporin.
Belimumab.
Rituximab or another biologic.
Mycophenolate.
Methotrexate.
Cyclophosphamide.
Voclosporin.
Nonsteroidal anti-inflammatory drugs.
Aspirin.
Heparin or another anticoagulant.
Antihypertensive medicines.
Statins.
Proton-pump inhibitors.
Calcium and vitamin D.
Iron and other supplements.
Herbal or traditional preparations.

Medication reconciliation should use prescriptions, boxes, photographs or pharmacy records when possible.

The phrase “one lupus tablet” is not enough for safe pregnancy advice.

Identify Medication Withdrawal

I ask:

Was hydroxychloroquine stopped?
Was another maintenance medicine stopped?
Was the change planned?
Was a pregnancy-compatible replacement started?
Did symptoms appear afterward?
Did the woman stop treatment because she feared fetal harm?
Did a clinician instruct her to stop?
Was the medicine unavailable?
Did vomiting prevent absorption?
Was adherence reduced before conception?

A flare after medication withdrawal should not be mislabelled as an unavoidable effect of pregnancy.

Review Steroid Exposure and Complications

I document:

Current dose.
Dose at conception.
Recent dose increases.
Intravenous pulses.
Duration.
Previous adrenal-suppression advice.
Diabetes.
Hypertension.
Infection.
Osteoporosis.
Fracture.
Avascular necrosis.
Cataract or glaucoma.
Mood or sleep effects.

The pregnancy plan should avoid both errors:

Withholding steroids when organ-threatening inflammation requires treatment.
Using prolonged high-dose steroids when a pregnancy-compatible steroid-sparing plan is possible.

Review Blood-Pressure History Precisely

I ask:

What was the pre-pregnancy blood pressure?
Is chronic hypertension diagnosed?
Which arm and cuff size are used?
Are home readings available?
Was the device validated for pregnancy?
Were antihypertensive medicines changed?
Has severe hypertension occurred?
Was preeclampsia diagnosed previously?
Were urine protein and kidney function abnormal before hypertension?
Are headache, visual symptoms, upper-abdominal pain or breathlessness present?

One normal clinic reading does not erase repeated high home readings.

One high reading during pain or anxiety does not establish preeclampsia.

The pattern requires confirmation and context.

Review Symptoms by Organ System

Skin and Mucosa

Ask about:

Photosensitive rash.
Malar rash.
Discoid lesions.
Vasculitic lesions.
Livedo.
Mouth or nasal ulcers.
Hair loss beyond expected pregnancy change.
New itch or urticaria.
Drug eruption.
Infection.

Joints and Muscles

Ask about:

Morning stiffness.
Swelling.
Symmetry.
Functional limitation.
Muscle weakness.
Myalgia.
Previous inflammatory pattern.
Mechanical pelvic or back pain.
Reduced mobility.

Kidney and Urinary Symptoms

Ask about:

Foamy urine.
Blood in urine.
Reduced urine output.
Swelling.
Dysuria.
Fever.
Flank pain.
Previous urinary infection.
Rising blood pressure.

Absence of urinary symptoms does not exclude nephritis.

Cardiac and Pulmonary Symptoms

Ask about:

Chest pain.
Pleuritic pain.
Orthopnoea.
Breathlessness.
Fainting.
Palpitations.
Reduced exercise tolerance.
One-sided leg swelling.
Previous pulmonary hypertension.
Previous embolism.
Recent infection.

Neurological Symptoms

Ask about:

Severe headache.
Visual disturbance.
Seizure.
Confusion.
Focal weakness.
Sensory change.
Speech difficulty.
New psychiatric symptoms.
Previous neuropsychiatric lupus.
Migraine pattern.

Urgent causes must be excluded before symptoms are attributed to lupus.

Review Infection Exposure and Symptoms

I ask about:

Fever.
Chills.
Cough.
Urinary symptoms.
Diarrhoea.
Skin infection.
Dental infection.
Recent antibiotics.
Sick contacts.
Travel.
Tuberculosis exposure.
Immunosuppressive treatment.
Vaccination.
Recent hospitalisation.

Infection may:

Mimic flare.
Trigger flare.
Worsen pregnancy risk.
Become more severe under immunosuppression.
Alter laboratory values.

The diagnosis should not be guessed from fever and fatigue alone.

Review Nutrition, Weight and Functional Status

The history includes:

Pre-pregnancy weight.
Current weight gain.
Appetite.
Nausea and vomiting.
Protein intake.
Iron, vitamin B12 and folate intake.
Vitamin D.
Calcium.
Food restriction.
Salt intake.
Diabetes.
Kidney-related dietary advice.
Mobility.
Fatigue.
Work demands.
Sleep.
Financial and family support.

Nutrition does not treat active lupus nephritis.

It supports maternal reserve, blood pressure, bone health, anaemia correction, glucose control and recovery.

The disease-specific nutrition approach will be discussed in Part 3.

What I Ask Patients to Bring

Please bring every available:

Rheumatology summary.
Nephrology summary.
Previous kidney biopsy report.
Previous hospital discharge summary.
Antibody reports.
Complement and anti-double-stranded DNA trends.
Blood-count reports.
Creatinine and kidney-function reports.
Urine protein measurements.
Urinalysis and sediment reports.
Blood-pressure records.
Echocardiogram or pulmonary reports when relevant.
Thrombosis records.
Anticoagulation plan.
Previous pregnancy records.
Placental histology.
Neonatal records.
Earliest dating scan.
Current ultrasound reports.
Complete medication list.
Medicine boxes or photographs when necessary.

Missing records should never prevent consultation.

The story can still be reconstructed from the information available.

In SLE, the timeline is a diagnostic tool. It shows whether pregnancy began with quiet disease, whether treatment protection changed and whether today’s abnormality is new or part of an established pattern.

The Investigation Map

Testing should answer defined questions:

Is lupus active?
Is kidney disease present?
Is a renal change inflammatory, chronic or pregnancy related?
Is preeclampsia developing?
Is infection present?
Is thrombosis risk altered?
Which antibodies change fetal or placental management?
Are medicines causing toxicity?
Is the fetus growing appropriately?
Would the result change treatment, surveillance or birth planning?

Not every test is required at every visit.

Testing without a clinical question can create noise.

1. Full Blood Count

A full blood count assesses:

Haemoglobin.
White blood cells.
Lymphocytes.
Platelets.

Abnormalities may reflect:

SLE activity.
Medication.
Infection.
Iron, vitamin B12 or folate deficiency.
Haemolysis.
Pregnancy-related dilution.
Preeclampsia or HELLP syndrome.
Bleeding.
Another haematological disorder.

The trend matters more than one isolated value.

2. Blood Film and Haemolysis Assessment

When anaemia or thrombocytopenia is unexplained, assessment may include:

Blood film.
Reticulocyte count.
Lactate dehydrogenase.
Bilirubin.
Haptoglobin.
Direct antiglobulin testing.
Iron studies.
Vitamin B12.
Folate.

The purpose is to distinguish:

Autoimmune haemolysis.
Microangiopathic haemolysis.
Nutritional deficiency.
Blood loss.
Medication effect.
Another cause.

Schistocytes, rising liver enzymes, low platelets and hypertension may suggest a pregnancy-related microangiopathic process.

They are not interpreted separately from the clinical picture.

3. Kidney Function

Kidney assessment may include:

Serum creatinine.
Urea.
Electrolytes.
Estimated kidney function outside pregnancy.
Trend from the pre-pregnancy baseline.
Urine output.
Serum albumin.
Blood pressure.

Creatinine normally falls during healthy pregnancy because filtration increases.

A creatinine value that appears “normal” by a non-pregnant laboratory range may still represent deterioration from the woman’s pregnancy baseline.

The trend deserves attention.

4. Urinalysis

Urinalysis may identify:

Protein.
Blood.
Leukocytes.
Nitrites.
Glucose.
Ketones.
Specific gravity.

Dipstick protein is a screening result.

It is affected by concentration, infection and other factors.

New or increasing protein should be quantified.

5. Urinary Sediment

Microscopy may identify:

Red blood cells.
Dysmorphic red cells.
White blood cells.
Red-cell casts.
White-cell casts.
Granular casts.
Bacteria.
Contamination.

An active urinary sediment may support lupus nephritis.

A bland sediment is more typical of preeclampsia.

Neither finding should be used alone. ^[5]

6. Quantification of Proteinuria

Proteinuria may be quantified with:

Urine protein-to-creatinine ratio.
Albumin-to-creatinine ratio in selected renal contexts.
Timed urine collection when clinically required.

The same method should be used consistently when possible.

Proteinuria can occur with:

Active lupus nephritis.
Previous renal damage.
Preeclampsia.
Chronic hypertension.
Diabetes.
Urinary infection.
Another kidney disease.

Protein quantity alone does not reliably distinguish lupus nephritis from preeclampsia.

7. Urine Culture

Urine infection may cause:

Protein.
Blood.
White cells.
Symptoms.
Fever.
Kidney involvement.

Culture may be required when infection is suspected or screening is indicated.

A contaminated sample should not be interpreted as active nephritis.

8. Complement

C3 and C4 may help assess lupus activity.

Interpretation should consider:

Pre-pregnancy level.
Early-pregnancy level.
Trend.
Anti-double-stranded DNA.
Symptoms.
Urine findings.
Kidney function.
Infection.

Complement often rises physiologically during pregnancy.

A fall from the woman’s pregnancy baseline may be clinically meaningful even when the value remains within the laboratory reference range.

Low or falling complement supports lupus activity.

It does not diagnose a flare alone. ^[1,5]

9. Anti-Double-Stranded DNA Antibodies

Anti-double-stranded DNA trends may support lupus activity, particularly when rising values accompany:

New symptoms.
Falling complement.
Active urinary sediment.
Rising proteinuria.
Kidney-function change.
Blood-count change.

Persistently elevated antibodies may occur without clinical flare.

Treatment should not be changed solely to normalise one antibody result.

10. Inflammatory Markers

Erythrocyte sedimentation rate may rise in normal pregnancy and with anaemia.

It is therefore difficult to interpret as a stand-alone lupus activity marker.

C-reactive protein may help when:

Infection is suspected.
Significant serositis or synovitis is present.
Another inflammatory process is being assessed.

A normal inflammatory marker does not exclude lupus activity.

An elevated marker does not prove flare.

11. Liver Tests

Liver assessment may include:

AST.
ALT.
Bilirubin.
Alkaline phosphatase interpreted in pregnancy context.
Other tests according to symptoms.

Abnormal liver tests may reflect:

Preeclampsia or HELLP syndrome.
Medication.
Infection.
Fatty liver.
Gallbladder disease.
Autoimmune liver disease.
Another condition.

They should not be attributed automatically to SLE.

12. Serum Uric Acid

Uric acid may rise in preeclampsia.

A normal value may be seen in active lupus nephritis.

Uric acid can also be affected by:

Kidney function.
Diet.
Medication.
Gestational age.
Other maternal conditions.

It may support the differential diagnosis.

It is not a definitive test.

13. Antiphospholipid-Antibody Profile

Testing includes:

Lupus anticoagulant.
Anticardiolipin IgG and IgM.
Anti-beta-2 glycoprotein I IgG and IgM.

The profile should be established before pregnancy or early in pregnancy when not already documented.

Interpretation requires:

Clinical history.
Persistence.
Anticoagulation status.
Laboratory method.
Previous results.

Repeating the full panel throughout pregnancy without a clinical reason is not automatically useful.

The diagnosis and treatment plan should be based on the established APS framework. ^[1,2]

14. Anti-Ro/SSA and Anti-La/SSB Antibodies

These antibodies should be documented before or early in pregnancy.

They influence counselling about:

Neonatal lupus.
Congenital heart block.
Fetal cardiac assessment.
Hydroxychloroquine.
Previous affected pregnancy.

They are not markers of lupus flare severity.

The detailed fetal-heart plan will be discussed later.

15. Baseline Liver, Glucose and Medication Monitoring

Medication-specific assessment may include:

Liver tests.
Kidney function.
Blood count.
Glucose.
Blood pressure.
Drug levels for selected medicines.
Eye monitoring for hydroxychloroquine according to long-term treatment guidance.
Infection screening before or during immunosuppression.

The monitoring should match:

The medicine.
Dose.
Organ function.
Pregnancy stage.
Disease activity.
Specialist plan.

16. Blood Pressure and Preeclampsia Assessment

Assessment may include:

Correct cuff size.
Repeated measurement.
Home readings when appropriate.
Symptoms.
Urine protein.
Platelets.
Creatinine.
Liver tests.
Haemolysis assessment.
Fetal growth.
Placental and fetal surveillance.
Angiogenic-marker testing where locally validated and clinically available.

Preeclampsia can occur without massive proteinuria.

Severe features may involve:

Severe hypertension.
Platelet reduction.
Kidney dysfunction.
Liver involvement.
Pulmonary oedema.
Cerebral or visual symptoms. [4]

17. Angiogenic Biomarkers

Tests involving placental growth factor or the soluble fms-like tyrosine kinase-1 to placental growth factor ratio may assist assessment of suspected placental disease in some healthcare systems.

They may be helpful when:

Preeclampsia is suspected.
Lupus nephritis creates diagnostic uncertainty.
The test is validated for the gestational age and clinical setting.
The result is interpreted by the treating team.

They do not replace:

Blood pressure.
Maternal symptoms.
Kidney and liver assessment.
Urinary sediment.
Lupus serology.
Fetal assessment.
Clinical judgement.

Availability and recommendations differ between countries.

18. Echocardiography and Cardiac Assessment

Maternal cardiac testing may be indicated for:

Previous myocarditis.
Cardiomyopathy.
Valvular disease.
Libman–Sacks endocarditis.
Pulmonary hypertension.
Unexplained breathlessness.
Chest pain.
Abnormal examination.
Previous cardiac investigation requiring follow-up.

Testing may include:

Electrocardiogram.
Echocardiography.
Cardiac biomarkers.
Additional imaging according to urgency and pregnancy safety.

The investigation should answer a maternal cardiac question.

It is different from fetal echocardiography for anti-Ro/SSA or anti-La/SSB antibodies.

19. Pulmonary and Thrombosis Assessment

Possible pulmonary embolism or another serious pulmonary disorder requires urgent assessment.

Testing may include:

Clinical examination.
Oxygen saturation.
Electrocardiogram.
Chest imaging.
Compression ultrasound.
Echocardiography.
CT pulmonary angiography or ventilation–perfusion imaging according to the clinical setting.
Other specialist testing.

Pregnancy and SLE both increase diagnostic complexity.

Necessary imaging should not be withheld solely because the woman is pregnant when a serious maternal condition is suspected.

20. Infection Assessment

Testing is guided by symptoms and exposure.

It may include:

Urine culture.
Blood cultures.
Respiratory testing.
Chest imaging.
Viral testing.
Stool testing.
Tuberculosis or hepatitis assessment.
Other site-specific investigations.

Broad untargeted infection panels can create false positives and confusion.

The question should be clinically defined.

21. Fetal Dating and Viability

Early ultrasound establishes:

Gestational age.
Viability.
Number of fetuses.
Chorionicity in multiple pregnancy.
Early anatomy when assessable.

Accurate dating later supports interpretation of:

Fetal growth.
Preterm birth.
Surveillance.
Timing of birth.

22. Fetal Anatomy

A detailed fetal structural assessment is required according to routine and high-risk pregnancy care.

Additional review may be influenced by:

Maternal disease.
Medication exposure.
Diabetes.
Anti-Ro/SSA or anti-La/SSB antibodies.
Previous fetal abnormality.
Screening results.

A normal anatomy scan is reassuring.

It does not assess every future placental or rhythm complication.

23. Fetal Growth

Serial growth assessment is recommended in SLE because of increased risk of fetal growth restriction and stillbirth. ^[1]

The report should review:

Estimated fetal weight.
Abdominal circumference.
Growth velocity.
Amniotic fluid.
Placenta.
Doppler when indicated.

The detailed schedule and interpretation will be addressed in Part 4.

24. Kidney Biopsy During Pregnancy

Kidney biopsy may be considered in selected pregnant women when:

A new renal abnormality is substantial.
Lupus nephritis and another diagnosis cannot be distinguished adequately.
The result is likely to change treatment.
The gestational age and procedural risk are acceptable.
Nephrology, rheumatology, maternal–fetal medicine and the woman have discussed the alternatives.

Biopsy is not required for every rise in proteinuria.

The risk–benefit balance changes as pregnancy advances. ^[5]

25. Disease-Activity Tools

Validated lupus activity tools may support consistent assessment.

They may include pregnancy-adapted instruments.

A score should not replace:

The woman’s symptoms.
Examination.
Organ-specific assessment.
Laboratory trends.
Obstetric findings.
Specialist judgement.

The tool is useful when it improves communication and longitudinal comparison.

26. Frequency of Maternal Monitoring

ACR guidance supports assessment of SLE disease activity with clinical history, examination and laboratory testing at least once per trimester. ^[2]

Many women require more frequent review because of:

Active or recently active disease.
Lupus nephritis.
Hypertension.
APS.
Medication change.
Abnormal laboratory trend.
Obstetric complication.
New symptoms.

The schedule should be individualised.

“Once per trimester” is not a ceiling for high-risk disease.

The investigation map is complete only when every result has a purpose: confirm stability, identify flare, detect placental disease, guide treatment or change surveillance and birth planning.

Lupus Flare or Preeclampsia?

This is one of the most difficult and important distinctions in an SLE pregnancy.

Lupus nephritis and preeclampsia can both cause:

Hypertension.
Proteinuria.
Kidney-function change.
Oedema.
Thrombocytopenia.
Maternal symptoms.
Fetal growth restriction.
Preterm birth.

The two conditions may also occur together.

No single laboratory result reliably separates every case.

Why the Distinction Matters

The treatments are different.

Active lupus nephritis may require:

Immunosuppression.
Pregnancy-compatible disease control.
Nephrology and rheumatology management.
Continued pregnancy when maternal and fetal condition allow.
Delivery for obstetric or maternal–fetal indications—not as the sole treatment for inflammation.

Preeclampsia may require:

Blood-pressure treatment.
Maternal and fetal surveillance.
Magnesium sulfate when indicated.
Delivery according to gestational age and severity.

Treating preeclampsia as nephritis may delay necessary birth.

Treating nephritis as preeclampsia may lead to premature delivery without controlling maternal inflammation.

Timing Provides a Clue

Preeclampsia typically develops after 20 weeks of gestation or postpartum.

New hypertension and proteinuria before 20 weeks more strongly suggest:

Pre-existing kidney disease.
Active lupus nephritis.
Chronic hypertension.
Another renal or maternal disorder.

Timing is a clue.

It is not absolute proof.

A woman with previous nephritis may develop superimposed preeclampsia after 20 weeks.

Compare With the Baseline

The most valuable questions are:

Was proteinuria present before pregnancy?
What was the early-pregnancy protein level?
Was urinary sediment already abnormal?
What was the baseline creatinine?
What were the complement and anti-double-stranded DNA levels?
Was blood pressure elevated before 20 weeks?
Were extra-renal lupus symptoms present?
Is the current change sudden or gradual?

A baseline transforms interpretation.

Without it, chronic findings may be mistaken for new disease.

Features That Support Lupus Nephritis

Findings that may support active lupus nephritis include:

Active urinary sediment.
Dysmorphic red blood cells.
Red-cell or white-cell casts.
Falling complement.
Rising anti-double-stranded DNA antibodies.
Extra-renal lupus activity.
A flare pattern similar to previous nephritis.
Proteinuria or renal abnormality beginning before 20 weeks.
Response to immunosuppressive treatment.
Kidney-biopsy evidence when biopsy is clinically justified.

No single feature is diagnostic.

The pattern matters. ^[5]

Features That Support Preeclampsia

Findings that may support preeclampsia include:

New hypertension after 20 weeks.
A placental-disease pattern.
Severe headache or visual symptoms.
Upper-abdominal or epigastric pain.
Elevated liver enzymes.
Haemolysis.
Falling platelets.
Pulmonary oedema.
Rising uric acid.
Fetal growth restriction.
Abnormal placental Doppler.
An angiogenic-marker pattern supporting placental dysfunction where validated.
Improvement after delivery.

Preeclampsia can occur without severe proteinuria.

The diagnosis uses the complete maternal and placental picture. ^[4]

Proteinuria Does Not Distinguish Them Reliably

Proteinuria may increase because of:

Active lupus nephritis.
Chronic renal damage.
Preeclampsia.
Chronic hypertension.
Diabetes.
Infection.
Another kidney disease.

A large increase is clinically important.

It does not identify the cause by itself.

Urinary Sediment Is Helpful

Active sediment with casts or dysmorphic haematuria supports inflammatory glomerular disease.

Preeclampsia more often produces a bland sediment.

Interpretation may be limited by:

Urinary infection.
Vaginal contamination.
Catheter trauma.
Previous chronic findings.
Laboratory technique.

A clean sample and experienced microscopy improve usefulness.

Complement Requires Pregnancy-Aware Interpretation

Complement may rise during normal pregnancy.

A woman may have active lupus despite a value that remains within the general laboratory range if the level has fallen significantly from her pregnancy baseline.

Low or falling complement supports flare.

Normal or rising complement supports—but does not prove—preeclampsia rather than nephritis.

Complement can be affected by other inflammatory and immune processes.

Anti-Double-Stranded DNA Supports Lupus Activity

A clear rise in anti-double-stranded DNA antibodies may support nephritis when it occurs with:

Falling complement.
Active sediment.
Extra-renal symptoms.
Renal deterioration.
Rising proteinuria.

A stable value does not exclude nephritis.

A rise without clinical or renal change does not establish it.

Extra-Renal Lupus Activity Is Important

Concurrent findings such as:

New lupus rash.
Inflammatory arthritis.
Mouth or nasal ulcers.
Serositis.
Immune cytopenia.
Other established flare manifestations.

support lupus activity.

Preeclampsia does not cause a classic lupus rash or inflammatory arthritis.

Pregnancy discomfort and nonspecific symptoms should not be counted as extra-renal flare without assessment.

Platelets Can Fall in Both Conditions

Thrombocytopenia may reflect:

SLE.
Immune thrombocytopenia.
Preeclampsia.
HELLP syndrome.
APS-related microangiopathy.
Thrombotic thrombocytopenic purpura.
Medication.
Infection.
Gestational thrombocytopenia.
Another haematological condition.

The evaluation may require:

Baseline platelet count.
Blood film.
Haemolysis testing.
Liver tests.
Kidney function.
Blood pressure.
Neurological assessment.
Haematology input.

A falling platelet count should not be assigned automatically to lupus.

Liver Involvement May Point Toward Preeclampsia—but Is Not Exclusive

Elevated AST or ALT with hypertension and right-upper-abdominal or epigastric pain may support preeclampsia or HELLP syndrome.

Liver abnormalities may also reflect:

Medication.
Infection.
Gallbladder disease.
Fatty liver.
Autoimmune liver disease.
Thrombosis.
Another condition.

The obstetric and medical picture determines urgency.

Uric Acid Is an Adjunct

Higher uric acid may support preeclampsia.

Normal uric acid may be more consistent with lupus nephritis.

The result is influenced by:

Kidney function.
Gestational age.
Diet.
Medication.
Other maternal disease.

It should not decide treatment alone.

Angiogenic Markers May Help

Placental growth factor and the soluble fms-like tyrosine kinase-1 to placental growth factor ratio may help identify placental dysfunction in some clinical systems.

A result supporting preeclampsia may be useful when nephritis creates uncertainty.

Limitations include:

Gestational-age restrictions.
Different assays.
Local availability.
Different national recommendations.
Imperfect discrimination.
Coexistence of lupus nephritis and preeclampsia.

The test is an adjunct—not an independent diagnosis.

Fetal and Placental Findings Add Context

Preeclampsia may be accompanied by:

Fetal growth restriction.
Abnormal uterine- or umbilical-artery Doppler.
Placental dysfunction.
Reduced amniotic fluid.
Abnormal surveillance.

Lupus nephritis may also increase placental risk.

A normal fetal-growth scan does not exclude either maternal condition.

A placental-disease pattern strengthens concern for preeclampsia or APS-related disease.

Infection Can Mimic or Trigger Either Picture

Urinary infection, pyelonephritis or systemic infection may cause:

Proteinuria.
Blood in urine.
Fever.
Kidney-function change.
Inflammation.
Fetal compromise.
Worsening maternal disease.

Culture and infection assessment may be required before escalating immunosuppression.

A woman can have infection and flare simultaneously.

APS and Thrombotic Microangiopathy Must Remain in the Differential

Hypertension, thrombocytopenia, kidney dysfunction and placental disease may involve:

Preeclampsia.
APS.
Catastrophic APS.
Thrombotic thrombocytopenic purpura.
Complement-mediated thrombotic microangiopathy.
HELLP syndrome.
Lupus nephritis.
More than one condition.

Severe or atypical presentations require multidisciplinary assessment.

The response may involve maternal–fetal medicine, rheumatology, nephrology, haematology and intensive care.

Kidney Biopsy May Be Considered When the Answer Will Change Treatment

Biopsy may be useful when:

The diagnosis remains uncertain.
Renal dysfunction or proteinuria is substantial.
The result would change immunosuppressive treatment.
The procedural risk is acceptable.
Delivery is not already the immediate necessary action.

The decision should consider:

Gestational age.
Blood pressure.
Platelets.
Anticoagulation.
Bleeding risk.
Alternative evidence.
Maternal and fetal stability.

Biopsy is not performed merely to make the chart more complete. ^[5]

Sometimes Both Diagnoses Are Present

A woman with previous or active lupus nephritis may also develop superimposed preeclampsia.

Possible clues include:

Established renal disease followed by new hypertension.
New severe maternal symptoms.
New liver or platelet abnormalities.
Placental growth restriction.
An angiogenic-marker pattern supporting placental disease.
Continued evidence of lupus activity.

The treatment plan may need to address:

Inflammation.
Hypertension.
Thrombosis risk.
Fetal surveillance.
Timing of birth.

The presence of one diagnosis does not protect against the other.

Delivery Response Can Clarify the Retrospective Diagnosis

Preeclampsia begins to improve after delivery of the placenta, although maternal risk can persist or worsen initially postpartum.

Active lupus nephritis does not resolve simply because the placenta has been delivered.

Persistent:

Active urinary sediment.
Falling complement.
Rising anti-double-stranded DNA antibodies.
Extra-renal flare.
Renal dysfunction.

may support ongoing lupus activity.

Postpartum reassessment is essential.

Do Not Delay Urgent Obstetric Care While Seeking Diagnostic Perfection

Immediate maternal or fetal danger may require treatment before every uncertainty is resolved.

Urgent action may be required for:

Severe hypertension.
Eclampsia.
Pulmonary oedema.
Stroke symptoms.
Serious thrombocytopenia or haemolysis.
Maternal instability.
Non-reassuring fetal status.
Placental abruption.
Another emergency.

The team may need to treat both plausible processes while investigations continue.

The correct question is not “Which single test proves lupus or preeclampsia?” It is “Which diagnosis—or combination of diagnoses—best explains the timing, baseline, urine, serology, maternal findings and placental picture?”

The next part will explain Dr Tania’s nutrition-led approach, pregnancy-compatible lupus treatment, hydroxychloroquine, steroids, immunosuppressive medicines and the safety principles that prevent both undertreatment and avoidable exposure.

Nutrition-Led Approach

Dr Tania’s Nutrition-Led Approach

Nutrition is part of active lupus pregnancy care.

It supports:

Maternal energy.
Blood formation.
Bone health.
Blood-pressure control.
Glucose control.
Kidney health.
Placental function.
Appropriate pregnancy weight gain.
Recovery from infection or flare.
Tolerance of medicines.
Postpartum recovery.

Nutrition does not suppress active organ inflammation by itself.

It cannot replace hydroxychloroquine, corticosteroids, immunosuppressive treatment, aspirin, anticoagulation or another indicated medicine.

My approach is nutrition-led—not inflammation-denying. Food protects maternal reserve and metabolic health while pregnancy-compatible treatment controls the disease process that food cannot switch off.

There Is No Single “Lupus Diet”

No one diet has been proved to prevent every lupus flare or pregnancy complication.

A useful plan should be based on:

Current disease activity.
Kidney involvement.
Blood pressure.
Diabetes or steroid-related glucose risk.
Anaemia.
Maternal weight.
Nausea and appetite.
Food access.
Cultural diet.
Vegetarian or non-vegetarian preferences.
Current medicines.
Pregnancy stage.

A diet that is suitable for one woman with mild skin and joint disease may be unsafe for another woman with active nephritis, reduced kidney function or severe hypertension.

Adequate Intake Matters During Quiet Disease and Flare

A woman may eat less because of:

Nausea.
Mouth ulcers.
Reflux.
Joint pain.
Fatigue.
Infection.
Active disease.
Depression or anxiety.
Medication adverse effects.
Food aversion.
Financial or practical barriers.

Reduced intake may contribute to:

Weight loss or inadequate gain.
Anaemia.
Weakness.
Ketones.
Poor medication tolerance.
Constipation.
Reduced bone support.
Slower recovery.

The plan should correct the reason for poor intake rather than simply instructing the woman to “eat better.”

Protein Should Be Individualised

Protein supports:

Maternal tissues.
Placental growth.
Fetal growth.
Blood proteins.
Recovery.

Suitable sources may include:

Lentils.
Pulses.
Beans.
Soy foods.
Curd or yoghurt.
Paneer in an appropriate preparation and portion.
Milk when tolerated.
Eggs.
Fish.
Poultry.
Lean meat.
Nuts and seeds.

The amount should be individualised when there is:

Lupus nephritis.
Reduced kidney function.
Heavy proteinuria.
Nephrotic syndrome.
Diabetes.
Low maternal weight.
Fetal growth concern.
Twin pregnancy.

A very high-protein diet should not be prescribed automatically to replace protein lost in the urine.

Kidney function, urine protein, serum albumin, blood pressure and nephrology advice matter.

Salt Advice Must Match the Clinical Problem

Reducing excessive processed salt may help:

Blood-pressure control.
Oedema management.
Steroid-related fluid retention.
Cardiovascular health.

Extreme salt elimination is not routinely required.

Salt advice should consider:

Chronic hypertension.
Preeclampsia risk.
Kidney disease.
Heart disease.
Sodium level.
Vomiting.
Climate and sweating.
Total diet.
Clinician recommendations.

Swelling in pregnancy is not always caused by eating salt.

Sudden or marked swelling with headache, visual symptoms, upper-abdominal pain or high blood pressure requires medical assessment—not a stricter home diet.

Hydration Must Be Practical and Medically Safe

Adequate hydration supports:

Circulating volume.
Kidney function.
Constipation prevention.
Heat tolerance.
Medication use.
Recovery from vomiting or fever.

The plan should consider:

Kidney function.
Heart function.
Blood pressure.
Oedema.
Vomiting or diarrhoea.
Fever.
Climate.
Work and travel.
Diabetes.
Electrolytes.
Existing medical fluid advice.

A woman with kidney impairment, heart disease, severe hypertension or fluid overload should not be told to force large volumes without specialist review.

The aim is adequate intake—not competitive water drinking.

Anaemia Requires a Diagnosis

Anaemia may result from:

Iron deficiency.
Vitamin B12 deficiency.
Folate deficiency.
Inflammation.
Kidney disease.
Autoimmune haemolysis.
Medication.
Bleeding.
Pregnancy-related dilution.
More than one cause.

Treatment should follow the cause.

A woman with autoimmune haemolysis does not have the same treatment plan as a woman with iron deficiency.

A normal-looking diet does not exclude deficiency.

Testing may include:

Full blood count.
Ferritin and iron assessment.
Vitamin B12.
Folate.
Reticulocytes.
Haemolysis markers.
Kidney function.

Iron Should Not Be Taken Blindly

Iron is important when deficiency is present.

Unnecessary high-dose iron may cause:

Nausea.
Constipation.
Abdominal pain.
Poor adherence.
Confusion about the true cause of anaemia.

The preparation, dose and route should reflect:

Severity.
Gestational age.
Tolerance.
Response.
Inflammation.
Kidney disease.
Haemoglobinopathy.
Time available before birth.

Food supports iron intake.

It may not correct moderate or severe deficiency without supplementation.

Folate and Vitamin B12 Need Attention

Folate and vitamin B12 are important for:

Blood formation.
Fetal development.
Neurological health.

Risk may increase with:

Vegetarian or vegan diets.
Malabsorption.
Previous bariatric surgery.
Severe vomiting.
Limited food intake.
Certain medicines.
Previous deficiency.

Folate supplementation should follow pregnancy guidance and the woman’s medication history.

A woman recently exposed to a folate-antagonist medicine requires urgent specialist review rather than relying on routine supplementation alone.

Calcium and Vitamin D Support Bone Health

SLE may increase bone-health concerns because of:

Glucocorticoid exposure.
Reduced physical activity.
Vitamin D deficiency.
Photosensitivity and sun avoidance.
Kidney disease.
Inflammation.
Low dietary calcium.
Previous fracture.
Osteoporosis.
Pregnancy and breastfeeding demands.

The plan may include:

Dietary calcium.
Vitamin D testing when indicated.
Supplementation.
Weight-bearing activity when safe.
Review of steroid exposure.
Bone-health assessment.

Very high-dose vitamin D should not be taken without clinical supervision.

Kidney disease can change vitamin D, calcium and phosphate management.

Steroid Treatment Changes the Nutrition Plan

Glucocorticoids may increase:

Appetite.
Blood glucose.
Blood pressure.
Fluid retention.
Weight gain.
Bone loss.
Infection risk.
Muscle weakness.

Nutrition may need to emphasise:

Regular balanced meals.
Appropriate carbohydrate distribution.
Adequate protein.
Calcium and vitamin D.
Reduction of excessive processed salt.
Avoidance of frequent high-sugar drinks.
Appropriate weight gain.
Glucose monitoring when indicated.

Diet can reduce metabolic burden.

It should not be used to deny a steroid that is required to protect maternal organs.

Glucose Control Deserves Early Attention

SLE pregnancy may involve diabetes risk because of:

Glucocorticoids.
Maternal weight.
Family history.
Previous gestational diabetes.
Polycystic ovary syndrome.
Reduced activity.
Other metabolic risk.

Assessment may include:

Early glucose testing when indicated.
Routine gestational-diabetes screening.
Home glucose monitoring during substantial steroid treatment.
Nutrition review.
Medication when required.

A glucose rise caused partly by steroids still requires treatment.

The answer is not always to stop the steroid abruptly.

Omega-3 Foods Can Be Part of a Balanced Diet

Appropriate omega-3 sources may include:

Low-mercury fish prepared safely.
Nuts.
Seeds.
Other foods according to the woman’s diet.

These foods may support general cardiovascular and nutritional health.

Omega-3 food or supplements should not be presented as treatment for:

Active lupus nephritis.
APS.
Thrombosis.
Congenital heart block.
Preeclampsia.
A severe flare.

Supplement quality, dose and bleeding risk matter, particularly when aspirin or anticoagulation is being used.

Food Safety Matters More Under Immunosuppression

Pregnancy and immunosuppressive treatment may increase the consequences of infection.

Food-safety advice includes:

Avoiding unpasteurised milk products.
Avoiding undercooked eggs, meat and fish.
Washing produce.
Preventing cross-contamination.
Refrigerating food promptly.
Reheating leftovers safely.
Avoiding foods restricted by local pregnancy guidance.
Paying attention to water safety during travel.

“Natural” does not mean infection-free.

Herbal and “Immune-Boosting” Products Require Caution

I do not recommend unregulated products claiming to:

Boost immunity.
Detoxify the body.
Clean the kidneys.
Replace steroids.
Cure lupus.
prevent miscarriage.
thin the blood naturally.
normalise antibodies.

Potential problems include:

Unknown ingredients.
Contamination.
Liver or kidney toxicity.
Drug interactions.
Bleeding.
Blood-pressure effects.
Glucose effects.
Stimulation of immune pathways.
Inconsistent dosing.
Lack of pregnancy safety data.

SLE is not caused by a weak immune system that simply needs to be “boosted.”

Supplements Must Have a Defined Purpose

Possible supplements may include:

Folic acid.
Iron.
Vitamin B12.
Vitamin D.
Calcium.
Other nutrients for a documented need.

Each supplement should have:

An indication.
A safe dose.
A review of kidney function.
A review of medication interactions.
A stop or reassessment plan.

Multiple overlapping prenatal, bone-health and wellness products can produce unintended excess.

Extreme Elimination Diets Can Cause Harm

I do not recommend unsupervised removal of:

All dairy.
All gluten.
All carbohydrates.
All fruit.
All pulses.
All fats.
Multiple food groups.
Salt entirely.
Protein broadly.

Elimination may be appropriate for:

A diagnosed allergy.
Coeliac disease.
A documented intolerance.
Kidney or metabolic indications.
Another defined clinical reason.

It should not be based on fear that one ordinary food is feeding lupus.

Fasting Requires Individual Review

Prolonged fasting may increase the risk of:

Dehydration.
Hypoglycaemia.
Ketones.
Reduced medication tolerance.
Missed doses.
Headache.
Weakness.
Poor weight gain.
Kidney stress.
Thrombosis in a woman with additional risk factors.

The discussion should consider:

Gestational age.
Disease activity.
Kidney function.
Diabetes.
Blood pressure.
APS.
Anticoagulation.
Medication timing.
Climate.
Fetal growth.
The woman’s faith and values.

A medically high-risk pregnancy may require modified observance or exemption after respectful counselling.

Weight Gain Should Be Appropriate—not Feared

Too little weight gain may reflect:

Poor intake.
Active disease.
Severe nausea.
Infection.
Food insecurity.
Fear of steroids.
Over-restriction.

Excessive gain may reflect:

Calorie excess.
Reduced activity.
Steroid appetite.
Fluid retention.
Kidney disease.
Hypertension.
Preeclampsia.

Weight should be interpreted with:

Pre-pregnancy body mass index.
Oedema.
Fetal growth.
Disease activity.
Blood pressure.
Glucose.
Kidney function.

Physical Activity Supports Health When Clinically Safe

Appropriate activity may support:

Cardiovascular health.
Glucose control.
Bone health.
Mood.
Sleep.
Muscle function.
Thrombosis prevention.

The plan may require modification for:

Active arthritis.
Severe fatigue.
Cardiopulmonary disease.
Placental complications.
Hypertension.
Bleeding.
Preterm-labour risk.
Another obstetric indication.

Routine bed rest is not a nutrition or lupus treatment.

Nutrition Cannot Treat APS or Replace Anticoagulation

Food cannot replace:

Low-dose aspirin.
Prophylactic heparin.
Therapeutic anticoagulation.
Thrombosis assessment.
Placental surveillance.

A woman should not reduce or stop prescribed treatment because a food, spice or supplement is described as a natural blood thinner.

Dietary changes may alter bleeding or medication risk.

They should be discussed with the treating team.

Nutrition Cannot Treat Anti-Ro/SSA-Related Fetal Risk

No diet has been proved to prevent congenital heart block or neonatal lupus.

The relevant care involves:

Antibody documentation.
Hydroxychloroquine when indicated.
Specialist counselling.
A fetal cardiac plan.
Newborn assessment.

Food supports the mother.

It does not remove antibody-mediated fetal risk.

Nutrition During a Flare

During active disease, priorities may include:

Adequate energy.
Adequate protein according to kidney status.
Medication tolerance.
Glucose control.
Blood-pressure support.
Infection-safe food.
Anaemia treatment.
Correction of vomiting or diarrhoea.
Prevention of dehydration.
Maintenance of practical intake during hospital care.

A flare is not the time for an aggressive detox, weight-loss or elimination plan.

Dr Tania’s Clinical Interpretation

I do not prescribe the same nutrition plan for:

Quiet SLE without organ damage.
Active lupus nephritis.
Residual proteinuria with stable kidney function.
Nephrotic syndrome.
Chronic hypertension.
Steroid-induced hyperglycaemia.
APS on anticoagulation.
Anaemia from iron deficiency.
Autoimmune haemolysis.
Severe nausea.
Low maternal weight.
Excessive steroid-related gain.

The diet should respond to the woman’s actual disease, medicines, laboratory values and pregnancy.

Nutrition is treated as clinical support with measurable goals—not as a promise that food can replace the medicine protecting the mother’s organs.

Medicines & Safety

Medicines, Hydroxychloroquine and Safety

Pregnancy-compatible treatment is a protective part of SLE care.

The safest plan is rarely created by stopping every medicine.

It is created by:

Identifying which medicines are essential.
Replacing pregnancy-incompatible treatment before conception.
Maintaining disease control.
Using the lowest effective exposure where appropriate.
Monitoring maternal and fetal effects.
Planning breastfeeding and postpartum treatment before birth.

Professional recommendations should be applied to the woman’s organ involvement and disease severity. ^[1,2,3,5,6]

Do Not Stop Lupus Medicines Automatically

Abrupt treatment withdrawal may lead to:

Flare.
Lupus nephritis.
Organ damage.
Hospital admission.
High-dose rescue steroid use.
Preterm birth.
Maternal and fetal deterioration.

A woman should contact her rheumatology and obstetric team promptly when pregnancy is recognised.

She should not stop all treatment because a package insert advises discussing pregnancy.

Hydroxychloroquine Is Central Treatment

Hydroxychloroquine is recommended for most pregnant women with SLE.

SMFM recommends that women with SLE other than those with quiescent disease continue or initiate hydroxychloroquine during pregnancy.

For a woman with quiescent disease who is not already taking it, initiation may be considered through shared decision-making with rheumatology. ^[1]

Hydroxychloroquine may help:

Maintain disease control.
Reduce flare risk.
Reduce steroid requirement.
Support lupus-nephritis management.
Improve pregnancy planning.
Reduce recurrence risk of cardiac neonatal lupus in selected anti-Ro/SSA-positive women with a previously affected child.

It should not be presented as a guarantee against flare, preeclampsia, pregnancy loss or congenital heart block.

Hydroxychloroquine Is Not an Emergency Rescue Medicine

Hydroxychloroquine works as background disease-modifying treatment.

It does not rapidly control:

Severe active nephritis.
Major neurological lupus.
Severe haemolysis.
Pulmonary haemorrhage.
Another organ-threatening flare.

Additional treatment may be required.

Starting hydroxychloroquine should not delay urgent therapy for serious disease.

Adherence Matters

I ask:

Is the medicine taken every day?
Are doses missed because of nausea?
Is the tablet unavailable?
Has cost interrupted supply?
Did the woman stop it because she feared fetal harm?
Is there concern about eye toxicity?
Is another medicine or antacid affecting timing?
Is vomiting preventing absorption?

A prescription in the record does not prove that the medicine is being taken.

Non-adherence should be addressed without blame.

Hydroxychloroquine Dose Requires Individual Review

The prescribed dose should consider:

Current disease control.
Maternal weight.
Kidney function.
Long-term cumulative exposure.
Retinal-toxicity risk.
Previous flare after dose reduction.
Specialist plan.

Pregnancy is not a reason to reduce an effective dose automatically.

Kidney impairment may increase toxicity concerns and requires specialist monitoring.

Eye Monitoring Remains Important

Long-term hydroxychloroquine use requires retinal-toxicity surveillance according to ophthalmology guidance.

Pregnancy does not remove that need.

An overdue eye assessment should be organised without stopping the medicine abruptly unless a clinician identifies a specific reason.

Visual symptoms require prompt review.

Hydroxychloroquine and the Heart

Hydroxychloroquine can affect cardiac electrical conduction in uncommon situations.

Risk may be greater with:

Other QT-prolonging medicines.
Electrolyte disturbance.
Significant cardiac disease.
Overdose.
Severe kidney or liver impairment.

Routine fear should not replace rational review.

The complete medicine list and maternal cardiac history matter.

Glucocorticoids May Be Necessary

Prednisone or prednisolone may be used for lupus activity during pregnancy.

The placenta inactivates much of the maternal exposure compared with fluorinated steroids.

The aim is to use:

The lowest effective dose.
The shortest effective duration.
A steroid-sparing pregnancy-compatible medicine when appropriate.
Appropriate monitoring.

Steroid treatment should match the severity and organ involved.

Mild and Severe Flares Are Not Treated Identically

A mild skin or joint flare may require:

Local therapy.
Hydroxychloroquine optimisation.
A limited systemic treatment plan.
Review for infection or another diagnosis.

A severe renal, neurological, pulmonary, cardiac or haematological flare may require:

Hospital admission.
Intravenous corticosteroids.
Additional immunosuppression.
Organ-specific support.
Multidisciplinary care.

Fear of medication should not delay treatment that protects maternal organ function.

Steroid Risks Must Be Monitored

Glucocorticoids may increase:

Blood glucose.
Blood pressure.
Infection risk.
Weight gain.
Fluid retention.
Bone loss.
Muscle weakness.
Mood and sleep disturbance.
Eye complications.
Adrenal suppression with prolonged exposure.

Monitoring may include:

Blood pressure.
Glucose.
Weight.
Infection symptoms.
Bone support.
Eye review.
Anaesthetic or endocrine planning when long-term exposure is substantial.

The presence of risk does not mean the medicine should be withheld when needed.

Stress-Dose Steroids Are Not Automatic for Every Woman

The labour, surgery or acute-illness plan should consider:

Current steroid dose.
Duration.
Recent high-dose treatment.
Likelihood of adrenal suppression.
Clinical stress.
Anaesthetic plan.

Not every woman who has ever taken steroids requires stress-dose treatment.

The decision should be documented before birth when possible.

Azathioprine Is a Pregnancy-Compatible Option

Azathioprine is used in pregnancy when clinically indicated for:

SLE control.
Lupus nephritis maintenance.
Steroid-sparing treatment.
Other organ involvement.

Monitoring may include:

Full blood count.
Liver tests.
Infection.
Dose and adherence.
Interactions.
Maternal disease response.

The medicine should be prescribed and monitored by clinicians experienced in its use.

It should not be started or stopped from general website advice.

Tacrolimus and Ciclosporin May Be Used

Calcineurin inhibitors may be used during pregnancy for selected women with:

Lupus nephritis.
Other difficult-to-control disease.
Kidney transplantation.
A specialist maintenance plan.

Monitoring may include:

Blood pressure.
Kidney function.
Potassium and magnesium.
Glucose.
Drug levels when required.
Interacting medicines.
Maternal disease response.

A rise in creatinine or blood pressure should not be assumed automatically to be lupus, preeclampsia or medicine toxicity.

The complete pattern must be reviewed.

Medication Levels Can Change During Pregnancy

Pregnancy may change:

Drug absorption.
Distribution.
Protein binding.
Kidney clearance.
Liver metabolism.

A dose that controlled disease before pregnancy may require review.

Dose changes should be based on:

Clinical activity.
Organ function.
Drug-level interpretation where established.
Toxicity.
Specialist guidance.

The goal is disease control without unnecessary exposure.

Belimumab Requires Individualised Decision-Making

Belimumab may be important for disease control in selected women.

Pregnancy data remain less extensive than for hydroxychloroquine or azathioprine.

The decision to continue, stop or initiate treatment should consider:

Severity of SLE.
Organ involvement.
Previous response.
Risk of flare if withdrawn.
Alternative pregnancy-compatible treatment.
Timing of exposure.
Maternal preference.
Rheumatology and maternal–fetal medicine advice.

SMFM advises that decisions about biologics during pregnancy be individualised with rheumatology. ^[1]

Rituximab May Be Considered for Serious Disease

Rituximab may be considered in selected situations such as severe or organ-threatening disease when the expected maternal benefit outweighs fetal and neonatal uncertainty.

Later-pregnancy exposure may affect neonatal B cells.

The plan may require:

Neonatal blood-count or immune assessment.
Infection vigilance.
Coordination of infant live-vaccine timing.
Paediatric review.

It is not a routine first-line medicine for every pregnant woman with SLE.

Anifrolumab and Other Newer Therapies

Pregnancy data for newer targeted treatments may be limited.

The decision should consider:

Available human data.
Animal data.
Drug half-life.
Placental transfer.
Disease severity.
Alternatives.
Timing of pregnancy.
Breastfeeding plans.
Specialist recommendations.

“New” does not mean unsafe in every circumstance.

It also does not mean adequately studied.

Mycophenolate Is Pregnancy Incompatible

Mycophenolate mofetil and mycophenolic acid are associated with pregnancy loss and a characteristic pattern of fetal malformation.

SMFM recommends stopping mycophenolate at least six weeks before attempting pregnancy. ^[1]

The preconception plan should include:

A pregnancy-compatible replacement.
Time to confirm disease control.
Effective contraception during transition.
Review of kidney and lupus activity.
Specialist counselling.

Stopping mycophenolate without replacement can expose the woman to renal flare.

Pregnancy During or Soon After Mycophenolate Exposure

When pregnancy occurs during mycophenolate treatment or before the planned interval has passed:

Do not panic.
Contact rheumatology and maternal–fetal medicine urgently.
Confirm exposure dates.
Review dose.
Substitute treatment safely.
Assess disease activity.
Discuss fetal risk.
Offer detailed ultrasound and other appropriate counselling.
Respect the woman’s informed decisions.

Exposure does not mean that every fetus will be affected.

It requires time-sensitive specialist assessment.

Methotrexate Is Pregnancy Incompatible

Methotrexate must not be used as routine lupus treatment during pregnancy.

SMFM recommends discontinuing it one to three months before attempting conception. ^[1]

When pregnancy occurs during or soon after exposure:

Stop further doses under urgent clinical advice.
Confirm the timing and dose.
Contact maternal–fetal medicine and rheumatology.
Review folate management.
Discuss fetal risk and assessment.
Maintain lupus control with a safe alternative.

Routine prenatal folic acid is not a substitute for specialist exposure counselling.

Cyclophosphamide Is Generally Avoided

Cyclophosphamide is associated with fetal and fertility risk.

It is generally avoided before conception and during pregnancy.

In rare life-threatening maternal disease, specialist teams may consider its use after the first trimester when no safer effective alternative exists.

The decision requires:

Clear maternal indication.
Gestational-age assessment.
Discussion of fetal and fertility risks.
Consideration of alternatives.
Maternal–fetal medicine, rheumatology and relevant organ-specialist input.
Informed consent.

It should never be presented as routine pregnancy treatment.

Voclosporin Has Insufficient Pregnancy Evidence

Voclosporin may be used for lupus nephritis outside pregnancy.

Pregnancy evidence is insufficient for routine use.

A woman receiving it should have preconception review and transition planning.

The medicine should not be stopped without protecting renal disease with an appropriate alternative.

Leflunomide Requires Specialist Management

Leflunomide is not a routine SLE medicine, but some women may have received it for overlapping inflammatory disease.

It is pregnancy incompatible.

Preconception management may require:

Discontinuation.
A drug-elimination procedure.
Laboratory confirmation according to specialist guidance.
Effective contraception.
A pregnancy-compatible replacement.

An unplanned exposure requires urgent rheumatology and fetal-risk counselling.

Nonsteroidal Anti-Inflammatory Drugs Have Gestational Limits

SMFM recommends that prolonged NSAID use beyond 48 hours generally be avoided during pregnancy.

COX-2 inhibitors and full-dose aspirin should be avoided.

NSAID risk changes with gestational age and may include:

Fetal kidney effects.
Reduced amniotic fluid.
Premature constriction or closure of the ductus arteriosus later in pregnancy.
Bleeding.
Maternal kidney or blood-pressure effects. [1]

Short-term use, when considered, should be prescribed for a clear reason and gestational window.

Low-Dose Aspirin Is Different From Full-Dose Aspirin

Low-dose aspirin may be recommended in SLE to reduce preeclampsia risk.

SMFM recommends beginning low-dose aspirin at 12 weeks of gestation and continuing until delivery in patients with SLE. ^[1]

The plan should consider:

Allergy.
Bleeding.
Platelet count.
Anticoagulation.
Planned procedures.
Local guidance.
Individual contraindications.

Aspirin used for preeclampsia prevention is not the same as high-dose aspirin used for pain.

Paracetamol Does Not Treat Lupus Activity

Paracetamol may help fever or pain when clinically appropriate.

It does not treat:

Lupus inflammation.
Nephritis.
Serositis.
APS.
Preeclampsia.
Organ-threatening disease.

Persistent pain or fever requires assessment of the cause.

Symptom relief should not delay diagnosis.

Antihypertensive Medicines Must Be Reviewed

Women with lupus nephritis or chronic hypertension may enter pregnancy taking medicines that are not pregnancy compatible.

Angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers require preconception or early-pregnancy review.

The transition should protect:

Blood-pressure control.
Kidney function.
Maternal safety.

Pregnancy-compatible options are selected according to:

Blood pressure.
Kidney function.
Heart rate.
Other maternal conditions.
Tolerance.
Local guidance.

A medication should not be stopped without a replacement plan when hypertension is significant.

Diuretics Require a Defined Indication

Diuretics may be appropriate for:

Heart failure.
Pulmonary oedema.
Significant fluid overload.
Another specialist indication.

They are not routinely used simply because pregnancy swelling is present.

The plan should consider:

Circulating volume.
Kidney function.
Electrolytes.
Blood pressure.
Placental perfusion.
Maternal cardiac status.

Anticoagulants Will Be Discussed With APS

Heparin does not cross the placenta and may be used when indicated.

Warfarin and other anticoagulants require diagnosis-specific pregnancy planning.

The correct regimen depends on:

Previous thrombosis.
APS criteria.
Antibody profile.
Mechanical heart valve.
Bleeding risk.
Gestational stage.
Delivery and anaesthetic planning.

The detailed APS section will follow in Part 4.

Infection Prevention Is Part of Medication Safety

Immunosuppressed women should receive clear advice on:

Fever.
Urinary symptoms.
Respiratory symptoms.
Wound or skin infection.
Food safety.
Vaccination.
Sick contacts.
Travel.
When to seek urgent care.

A flare and infection may occur together.

Increasing immunosuppression without considering infection can be dangerous.

Vaccination Requires Timing and Treatment Awareness

Non-live vaccines recommended during pregnancy may be given according to current guidance and individual risk.

Live vaccines are generally avoided during pregnancy.

The plan should consider:

Current immunosuppression.
Previous vaccine response.
Gestational timing.
Travel.
Planned biologic therapy.
Infant vaccine implications after selected late-pregnancy biologic exposure.

Vaccination should be coordinated—not avoided automatically because the woman has lupus.

Medicine Monitoring Should Be Written

The plan should state:

Which medicines continue.
Which medicines change.
Why each medicine is used.
Required blood tests.
Blood-pressure monitoring.
Glucose monitoring.
Kidney and urine monitoring.
Eye monitoring.
Infection precautions.
Who prescribes each treatment.
Who responds to abnormal results.
Labour and surgical considerations.
Breastfeeding compatibility.
Postpartum dose plan.

A woman should not be left to coordinate conflicting prescriptions between specialists by herself.

Dr Tania’s Clinical Interpretation

I do not use the same medication response for:

Quiet SLE controlled with hydroxychloroquine.
Active lupus nephritis on mycophenolate.
Severe steroid-dependent disease.
Previous cyclophosphamide exposure.
APS requiring anticoagulation.
Anti-Ro/SSA positivity.
Chronic kidney impairment.
Unplanned pregnancy during an incompatible medicine.
A mild skin flare.
Organ-threatening disease.

The safest plan protects both sides of the balance:

Avoid unnecessary fetal exposure.
Avoid maternal flare and organ damage caused by undertreatment.

Medication safety does not mean using no medicine. It means using the treatment with the clearest purpose, strongest pregnancy experience and lowest effective risk for the disease that is actually present.

The next part will explain antiphospholipid antibodies and APS, anti-Ro/SSA and anti-La/SSB antibodies, fetal cardiac risk, maternal and fetal surveillance, and the guideline differences that require transparent counselling.

Antiphospholipid Antibodies & APS

Antiphospholipid Antibodies and APS

Antiphospholipid antibodies are important in SLE because they may affect:

Maternal thrombosis.
Placental function.
Pregnancy loss.
Fetal growth.
Preeclampsia.
Preterm birth.
Anticoagulation.
Delivery and postpartum planning.

The antibody result should not be interpreted without the clinical history.

A positive antibody is not automatically antiphospholipid syndrome.

The Three Standard Antiphospholipid-Antibody Tests

The standard laboratory profile includes:

Lupus anticoagulant.
Anticardiolipin IgG and IgM.
Anti-beta-2 glycoprotein I IgG and IgM.

These tests are not interchangeable.

A woman may have:

One positive antibody.
More than one positive antibody.
Lupus anticoagulant alone.
Triple positivity.
A transient low-positive result.
Persistent moderate- or high-level positivity.
Previously positive results that later become negative.

The exact antibody, level, persistence and clinical history all matter.

Lupus Anticoagulant Does Not Mean the Blood Is Thin

The name can be confusing.

Lupus anticoagulant is a laboratory phenomenon.

In the body, its presence may be associated with increased thrombosis and adverse pregnancy outcomes rather than bleeding.

It should not be interpreted from the word anticoagulant alone.

Persistence Matters

Classification-level antiphospholipid-antibody positivity generally requires persistence on repeat testing separated by at least 12 weeks.

A single positive result may occur with:

Infection.
Medication.
Laboratory variation.
Temporary immune activation.
Another condition.

Pregnancy management may still require individual review before confirmatory testing is complete when:

A previous thrombosis has occurred.
A serious placental complication has occurred.
The lupus anticoagulant is strongly positive.
Several antibodies are positive.
The current pregnancy is already high risk.

The clinician should not wait mechanically for a repeat date when urgent maternal or pregnancy risk requires action.

Classification Criteria Are Not a Substitute for Clinical Diagnosis

APS classification criteria were designed to create consistent research groups.

Clinical diagnosis may require specialist judgement.

A woman may have:

Clear thrombotic APS.
Clear obstetric APS.
Persistent antibodies without APS.
A pregnancy history that does not meet formal criteria but remains clinically concerning.
Incomplete or unavailable old records.
A new event while testing is still being completed.

The plan should document both:

Whether classification criteria are met.
Whether the clinical team believes APS or another antibody-related risk is present.

Antiphospholipid Antibodies Without APS

Some women have persistent antiphospholipid antibodies but have never had:

Thrombosis.
Pregnancy morbidity meeting obstetric APS criteria.

SMFM suggests low-dose aspirin alone for women with SLE and antiphospholipid antibodies who do not have clinical events meeting APS criteria. ^[1]

ACR also conditionally recommends low-dose aspirin during pregnancy for antibody-positive women without obstetric or thrombotic APS, mainly as preeclampsia prophylaxis. ^[2]

Routine prophylactic heparin is not automatically recommended for every positive antibody result.

The decision may still be individualised when the woman has:

Triple positivity.
Strong lupus-anticoagulant positivity.
IVF pregnancy.
Advanced maternal age.
Additional thrombosis risk.
A serious non-criteria placental history.
More than one concerning factor.

Obstetric APS

Obstetric APS refers to the combination of appropriate persistent antibody findings and defined pregnancy morbidity without previous thrombosis.

The history may include:

Recurrent early pregnancy loss.
Fetal loss at or after 10 weeks.
Very preterm birth related to severe preeclampsia or placental insufficiency.
Other qualifying pregnancy morbidity according to the criteria being applied.

The exact:

Number of losses.
Gestational ages.
Ultrasound findings.
Fetal heartbeat history.
Placental diagnosis.
Delivery indication.
Antibody dates and values.

should be reconstructed.

The phrase recurrent miscarriage alone is not enough to establish obstetric APS.

Treatment of Obstetric APS Without Previous Thrombosis

SMFM suggests:

Low-dose aspirin.
Prophylactic unfractionated heparin or low-molecular-weight heparin.

for women who meet obstetric APS criteria and have no previous thrombotic event. ^[1]

ACR strongly recommends the same combination of low-dose aspirin and prophylactic-dose heparin, usually low-molecular-weight heparin, for obstetric APS. ^[2]

This treatment aims to reduce pregnancy morbidity and maternal thrombotic risk.

It does not guarantee live birth or prevent every placental complication.

Thrombotic APS

Thrombotic APS involves a previous venous or arterial thrombosis together with the appropriate antibody framework.

Possible events include:

Deep-vein thrombosis.
Pulmonary embolism.
Stroke.
Transient ischaemic attack.
Retinal thrombosis.
Unusual-site venous thrombosis.
Arterial thrombosis.
Recurrent thrombosis.

Pregnancy increases thrombotic risk.

The plan must consider:

Type of previous event.
Provoked or unprovoked event.
Antibody profile.
Recurrence.
Current long-term anticoagulant.
Kidney function.
Weight.
Bleeding history.
Delivery and anaesthetic planning.

Treatment of Thrombotic APS

SMFM recommends therapeutic unfractionated or low-molecular-weight heparin for pregnant women with previous thrombosis and antiphospholipid antibodies. ^[1]

ACR strongly recommends therapeutic-dose heparin, usually low-molecular-weight heparin, with low-dose aspirin throughout pregnancy and postpartum for thrombotic APS. ^[2]

The exact regimen belongs in an individual specialist plan.

A website should not prescribe a treatment dose.

Heparin Does Not Cross the Placenta

Unfractionated heparin and low-molecular-weight heparin do not cross the placenta.

They are therefore used when anticoagulation is required during pregnancy.

Potential maternal concerns include:

Bleeding.
Bruising.
Injection-site reactions.
Heparin-induced thrombocytopenia.
Bone loss with prolonged exposure, particularly with unfractionated heparin.
Difficulty coordinating procedures or neuraxial anaesthesia.
Dose accumulation in significant kidney impairment for selected preparations.

Treatment should include monitoring appropriate to the woman’s regimen and risk.

Low-Molecular-Weight Heparin and Unfractionated Heparin Are Not Identical

The choice may depend on:

Indication.
Prophylactic or therapeutic intensity.
Kidney function.
Body weight.
Bleeding risk.
Previous heparin reaction.
Need for rapid reversal.
Delivery timing.
Anaesthetic plan.
Local availability and protocol.

Low-molecular-weight heparin is commonly used for outpatient pregnancy treatment.

Unfractionated heparin may be selected in particular clinical or peripartum situations.

The medicine should not be changed without coordination between obstetric, haematology and anaesthetic teams.

Aspirin and Heparin Have Different Roles

Low-dose aspirin affects platelet function.

Heparin provides anticoagulation through a different pathway.

One does not replace the other when combination treatment is indicated.

The woman should understand:

Why each medicine is prescribed.
When it begins.
Which dose category is being used.
What bleeding symptoms require review.
What happens around delivery.
What continues postpartum.

High-Risk Antibody Profiles

Risk may be greater with:

Lupus anticoagulant.
Double positivity.
Triple positivity.
Persistent moderate- or high-level antibodies.
Previous thrombosis.
Previous severe placental morbidity.
Coexisting SLE.
Additional cardiovascular or thrombosis risk factors.

A high-risk laboratory profile does not predict exactly what will happen.

It supports closer maternal and placental planning.

Placental Complications Can Occur Without a Lupus Flare

Antiphospholipid-antibody-related placental disease may occur while:

Lupus symptoms are quiet.
Complement is stable.
Anti-double-stranded DNA is unchanged.
No inflammatory flare is present.

Possible complications include:

Preeclampsia.
Fetal growth restriction.
Placental insufficiency.
Fetal loss.
Preterm birth.
Placental abruption.

Stable inflammatory lupus does not remove antibody-mediated placental risk.

Thrombosis Can Occur During Pregnancy or Postpartum

Pregnancy and the postpartum period increase venous-thrombosis risk.

Additional risk may come from:

APS.
Previous thrombosis.
Caesarean birth.
Immobility.
Infection.
Severe preeclampsia.
Postpartum haemorrhage followed by reduced mobility.
Obesity.
Hospital admission.
Nephrotic syndrome.
Central venous access.
Dehydration.
Smoking or nicotine use.
Other thrombophilia.

The prevention plan should be reassessed whenever the clinical situation changes.

Symptoms That Require Urgent Thrombosis Assessment

Seek urgent medical assessment for:

One-sided leg swelling.
Leg pain or tenderness.
Sudden breathlessness.
Chest pain.
Coughing blood.
Fainting.
New neurological deficit.
Difficulty speaking.
Facial asymmetry.
New severe visual disturbance.
Sudden severe headache.
A cold, painful or pale limb.
Another symptom suggesting thrombosis.

Do not wait for the next routine appointment.

Bleeding Symptoms Also Require Review

Contact the clinical team promptly for:

Heavy vaginal bleeding.
Persistent nose or gum bleeding.
Blood in urine or stool.
Large unexplained bruises.
Severe headache after trauma.
Prolonged bleeding from an injection site.
Dizziness or fainting.
Another concerning bleeding symptom.

Small injection-site bruises are common.

They should still be discussed if extensive, painful or increasing.

Platelet Count Requires Context

A low platelet count may reflect:

SLE.
Immune thrombocytopenia.
APS-related disease.
Preeclampsia or HELLP syndrome.
Heparin-induced thrombocytopenia.
Infection.
Medication.
Gestational thrombocytopenia.
Another haematological condition.

The timing, baseline and degree of change matter.

A falling platelet count during heparin treatment deserves prompt assessment.

Heparin-Induced Thrombocytopenia Is Uncommon but Serious

Heparin-induced thrombocytopenia is an immune complication associated with thrombosis risk.

Concern may arise with:

A substantial platelet fall.
New thrombosis.
Skin reaction at injection sites.
A compatible timing after heparin exposure.
Previous exposure.

The woman should not stop anticoagulation independently.

Urgent specialist assessment is required because an alternative anticoagulant may be needed.

Kidney Function Can Change Anticoagulation Planning

Significant kidney impairment may affect:

Low-molecular-weight-heparin clearance.
Dose selection.
Monitoring.
Choice between heparin preparations.
Bleeding risk.
Delivery planning.

The plan should use current kidney function rather than an old pre-pregnancy result.

Body Weight Can Change Dosing Decisions

Pregnancy weight changes may affect anticoagulant planning.

The team may consider:

Pre-pregnancy weight.
Current weight.
Indication.
Prophylactic or therapeutic treatment.
Kidney function.
Thrombosis recurrence.
Bleeding.
Local monitoring protocol.

Dose changes should be made by the prescribing team.

Anti-Factor Xa Monitoring Is Not Required for Every Woman

Anti-factor Xa monitoring may be considered in selected circumstances, such as:

Extreme body weight.
Kidney impairment.
Recurrent thrombosis.
Bleeding.
Uncertainty about therapeutic exposure.
A specialist protocol.

Routine monitoring for every woman is not universally recommended.

The result should be interpreted according to:

Timing after injection.
Assay.
Indication.
Dose.
Laboratory target used by the treating team.

Recurrent Pregnancy Complications Despite Standard Treatment

Pregnancy complications may recur despite low-dose aspirin and prophylactic heparin.

The first response should be to reassess:

Whether APS criteria are correct.
Whether the antibody profile is high risk.
Adherence.
Injection technique.
Dose and weight.
Kidney function.
Lupus activity.
Hypertension.
Fetal growth.
Other causes of pregnancy loss.
Other placental or maternal disease.

The treatment should not be escalated from frustration alone.

Hydroxychloroquine May Have an Adjunctive Role

A woman with SLE should generally continue hydroxychloroquine for lupus control.

ACR conditionally supports adding hydroxychloroquine for selected APS pregnancies with complications despite standard aspirin and heparin treatment. ^[2]

Hydroxychloroquine is not a substitute for heparin when anticoagulation is indicated.

It should not be presented as a guaranteed rescue treatment.

Prednisone Is Not Routine APS Prevention

ACR strongly recommends against adding prednisone routinely to aspirin and heparin for obstetric APS because maternal risks are not balanced by proven benefit. ^[2]

Steroids may still be required for:

Active SLE.
Immune thrombocytopenia.
Another inflammatory or haematological indication.

The indication should be stated clearly.

“APS treatment” and “lupus-flare treatment” should not be confused.

Intravenous Immunoglobulin Is Not Routine First-Line Treatment

Intravenous immunoglobulin is not routinely added to standard aspirin and heparin for uncomplicated obstetric APS.

It may be considered in selected, refractory or complex situations after specialist review.

Potential factors include:

Recurrent complications despite confirmed treatment.
Severe thrombocytopenia.
Another immune indication.
Contraindication to standard therapy.

It should not be presented as standard treatment for every antibody-positive pregnancy.

Statins Are Not Routine APS Pregnancy Treatment

Statins are not routine treatment for obstetric APS in pregnancy.

Specialist teams may consider selected use in research-informed or exceptionally high-risk circumstances.

The decision requires:

Clear indication.
Maternal cardiovascular and placental assessment.
Review of evolving evidence.
Informed discussion.

A statin should not be started from general website information.

Direct Oral Anticoagulants Are Generally Not Used for APS Pregnancy

Direct oral anticoagulants cross the placenta and are not standard pregnancy anticoagulants.

They are generally avoided during pregnancy.

Outside pregnancy, they may also be unsuitable for high-risk APS, particularly with triple positivity or arterial events.

A woman taking a direct oral anticoagulant who becomes pregnant requires prompt specialist transition planning.

She should not stop anticoagulation without an alternative.

Warfarin Requires Diagnosis-Specific Pregnancy Planning

Warfarin crosses the placenta.

It may cause fetal harm, with risk influenced by gestational timing and dose.

Most women with APS are transitioned to heparin during pregnancy.

Exceptional conditions, such as some mechanical heart valves, require a different specialist risk–benefit framework.

A woman who becomes pregnant while taking warfarin should seek urgent medical advice.

She should not stop treatment without a replacement anticoagulation plan.

Delivery and Anaesthetic Planning Must Begin Before Labour

The written plan should state:

Anticoagulant name.
Dose category.
Last planned dose before induction or caesarean birth.
What to do if labour begins unexpectedly.
What to do if the membranes rupture.
Whether neuraxial analgesia may be possible.
Platelet requirements.
Bleeding plan.
Postpartum restart timing.
Duration of postpartum treatment.
Which team can be contacted at any time.

The exact interval between the last heparin dose and neuraxial anaesthesia depends on:

Prophylactic or therapeutic dosing.
Heparin preparation.
Kidney function.
Platelet count.
Bleeding risk.
Anaesthetic guideline.

The woman should not guess the timing herself.

Induction May Be Used to Coordinate Anticoagulation Safely

A planned induction or caesarean birth may be considered when it helps coordinate:

Anticoagulant interruption.
Neuraxial analgesia.
Maternal disease.
Fetal surveillance.
Placental risk.
Specialist availability.

Anticoagulation alone does not automatically require caesarean birth.

The birth method should follow the complete obstetric picture.

Emergency Birth May Occur Before Anticoagulant Effect Has Cleared

When urgent maternal or fetal indications require birth:

Delivery should not be delayed solely to meet an ideal anaesthetic interval.
Neuraxial anaesthesia may be unavailable.
General anaesthesia may be required for urgent caesarean birth.
Bleeding risk should be assessed.
Reversal or blood-product planning may be needed.
Haematology, anaesthesia and obstetric teams should coordinate rapidly.

The woman should understand this possibility before labour.

Postpartum Thrombosis Risk Is High

The postpartum period includes:

A sudden change in blood volume.
Delivery-related tissue injury.
Reduced mobility.
Possible surgery.
Infection risk.
Continued APS risk.
Possible lupus flare.
Sleep deprivation and difficulty maintaining medication.

Anticoagulation should not disappear from the plan once the baby is born.

Postpartum Treatment After Obstetric APS

ACR strongly recommends prophylactic-dose anticoagulation for 6 to 12 weeks postpartum for women with obstetric APS. ^[2]

EULAR guidance supports continuing prophylactic heparin for 6 weeks after delivery in women treated with prophylactic heparin during pregnancy. ^[7]

The individual duration should consider:

Mode of birth.
Bleeding.
Mobility.
Infection.
Obesity.
Preeclampsia.
Other thrombosis risk.
Local guideline.
Haematology plan.

Postpartum Treatment After Thrombotic APS

Women with thrombotic APS usually require therapeutic anticoagulation postpartum.

Many require long-term anticoagulation beyond the postpartum period because of their previous thrombosis.

The plan should specify:

When anticoagulation restarts.
Which medicine is used.
Breastfeeding compatibility.
Monitoring.
Bleeding precautions.
Transition from heparin when appropriate.
Duration.
Who manages long-term treatment.

Breastfeeding and Anticoagulation

Unfractionated heparin and low-molecular-weight heparin are compatible with breastfeeding.

Warfarin is also generally considered compatible with breastfeeding.

Direct oral anticoagulants are generally avoided during breastfeeding because infant-safety evidence is insufficient and transfer varies by medicine.

The postpartum choice should consider:

APS diagnosis.
Long-term treatment need.
Maternal preference.
Kidney function.
Bleeding.
Monitoring access.
Infant factors.
Specialist guidance.

The broader lupus medicine and breastfeeding plan will be discussed in Part 4C.

Contraception Must Consider Thrombosis Risk

Estrogen-containing contraception may be unsuitable for women with:

Positive antiphospholipid antibodies.
APS.
Previous thrombosis.
Other major thrombosis risk.

Options may include:

Intrauterine contraception.
Progestin-only methods.
Barrier methods.
Permanent contraception when desired.
Other methods according to medical eligibility.

The choice should consider:

Anticoagulation.
Menstrual bleeding.
Platelet count.
Disease activity.
Reproductive plans.
Personal preference.

The Next Pregnancy Should Begin With the Previous APS Records

Please retain:

Every antiphospholipid-antibody report.
Dates and values.
Thrombosis records.
Imaging.
Previous pregnancy records.
Placental histology.
Aspirin and heparin regimens.
Dose changes.
Delivery anticoagulation plan.
Postpartum treatment.
Bleeding or thrombosis complications.

These records may prevent the next pregnancy from repeating diagnostic uncertainty.

Dr Tania’s Clinical Interpretation

I do not use the same plan for:

One transient low-positive anticardiolipin result.
Persistent lupus anticoagulant without a clinical event.
Triple-positive antibodies.
Recurrent early losses meeting obstetric APS criteria.
Previous fetal loss.
Previous severe placental disease.
Previous pulmonary embolism.
Previous arterial stroke.
Recurrent thrombosis on treatment.
APS with kidney impairment.
APS with thrombocytopenia.
APS with active lupus nephritis.

The plan should match:

Antibody risk.
Clinical history.
Maternal disease.
Pregnancy stage.
Placental findings.
Bleeding risk.
Delivery plan.
Postpartum risk.

Antiphospholipid antibodies are laboratory findings. APS is a clinical–laboratory diagnosis. Treatment should follow the woman’s actual thrombotic and obstetric risk—not fear created by one positive result.

The next part will explain anti-Ro/SSA and anti-La/SSB antibodies, neonatal lupus, congenital heart block, the important difference between ACR and SMFM fetal-echo recommendations, and the broader maternal and fetal surveillance plan.

Anti-Ro/SSA, Anti-La/SSB & Fetal Heart

Anti-Ro/SSA, Anti-La/SSB and the Fetal Heart

Anti-Ro/SSA and anti-La/SSB antibodies require a separate pregnancy discussion.

They are not:

Measures of current lupus activity.
Proof that the fetus will be affected.
The same as antiphospholipid antibodies.
A reason to stop hydroxychloroquine.
A reason for automatic preterm birth or caesarean delivery.

They matter because maternal antibodies can cross the placenta and, in a small proportion of pregnancies, contribute to neonatal lupus.

Test Once Before or Early in Pregnancy

ACR strongly recommends testing anti-Ro/SSA and anti-La/SSB antibodies once before or early in pregnancy in women with SLE and related rheumatic disease.

Because these antibodies generally persist and titres do not usually change in a way that guides pregnancy management, routine repeat testing during the same pregnancy is not recommended. ^[2]

The record should document:

Anti-Ro/SSA status.
Anti-La/SSB status.
Laboratory method when available.
Previous affected child.
Previous fetal or neonatal heart block.
Previous neonatal lupus rash.
Previous neonatal blood-count or liver abnormality.
Current hydroxychloroquine treatment.
The agreed fetal-cardiac plan.

Anti-Ro/SSA Is the Main Antibody Association

Anti-Ro/SSA antibodies are the main antibodies associated with cardiac neonatal lupus.

Anti-La/SSB may occur with anti-Ro/SSA and may add clinical context.

Isolated anti-La/SSB positivity without anti-Ro/SSA is less commonly associated with fetal cardiac disease.

The report should identify which antibody is actually present.

The phrase “neonatal lupus antibodies positive” is not sufficiently precise.

What Neonatal Lupus Means

Neonatal lupus describes antibody-associated findings that may include:

Congenital heart block.
Other fetal or neonatal cardiac inflammation.
Skin rash.
Low blood counts.
Liver-enzyme abnormalities.
Less commonly, other manifestations.

The name does not mean that the baby has inherited maternal SLE.

Most non-cardiac manifestations are temporary and improve as maternal antibodies disappear from the infant’s circulation.

Complete congenital heart block is different because established conduction-system scarring is usually permanent. ^[2,11]

The Absolute Cardiac Risk Is Low in a First At-Risk Pregnancy

In women with anti-Ro/SSA antibodies and no previously affected child, the risk of congenital complete heart block is approximately 1% to 2%.

A prospective study of anti-Ro/SSA-positive pregnancies reported complete heart block in approximately 2% of infants. ^[2,9]

This means:

Most exposed fetuses do not develop congenital heart block.
The antibody result still requires informed counselling.
Risk should be explained with absolute numbers rather than alarming language.

Previous Cardiac Neonatal Lupus Changes the Risk

After a previous child with cardiac neonatal lupus, recurrence risk is substantially higher.

A large registry study reported recurrence of cardiac neonatal lupus in approximately 17% of subsequent pregnancies. ^[10]

The recurrence is not determined reliably by:

Maternal symptoms.
Maternal diagnosis.
Fetal sex.
Whether the previous affected child required a pacemaker.
Whether the mother currently feels well.

A woman with a previously affected child requires early specialist planning.

A Previous Non-Cardiac Neonatal Lupus Manifestation Also Matters

A previous child with neonatal lupus rash, blood-count abnormality or liver involvement may increase concern in a later pregnancy.

The history should document:

Exact manifestation.
Timing.
Photographs or paediatric records when available.
Antibody status.
Whether the heart was assessed.
Whether another diagnosis was considered.

The recurrence discussion should be individualised with rheumatology, fetal medicine and paediatric cardiology.

When Cardiac Injury Usually Develops

Immune-mediated congenital heart block most often develops during the second trimester.

ACR’s surveillance recommendations focus on the period from 16 to 18 weeks through 26 weeks because clinically important new block is uncommon after that period. ^[2]

A normal early scan does not guarantee that the rhythm will remain normal.

A normal scan after the main risk window is reassuring but does not replace ordinary obstetric assessment.

Congenital Heart Block Is Not a Structural Heart Defect

Immune-mediated congenital heart block is primarily a disorder of electrical conduction.

The fetal heart may be structurally normal.

The condition may involve:

Prolongation of atrioventricular conduction.
Second-degree block.
Complete third-degree block.
Slow fetal heart rate.
Endocardial fibroelastosis.
Cardiomyopathy.
Valve or myocardial involvement in selected cases.

A normal structural anatomy scan does not by itself exclude a future rhythm problem.

What Fetal Echocardiography Can Assess

A specialist fetal echocardiogram may assess:

Fetal heart rate.
Rhythm.
Atrioventricular relationship.
Mechanical PR interval.
Ventricular function.
Valve function.
Evidence of inflammation.
Endocardial fibroelastosis.
Structural cardiac anatomy.
Hydrops or other fetal effects.

The examination is more detailed than simply listening to the fetal heart rate.

It still cannot guarantee that conduction will remain normal between assessments.

ACR and SMFM Do Not Give the Same Routine Surveillance Recommendation

This difference should be explained openly.

ACR Approach

For anti-Ro/SSA- and/or anti-La/SSB-positive women with no previously affected infant, ACR conditionally recommends serial fetal echocardiography less often than weekly, beginning between 16 and 18 weeks and continuing through 26 weeks.

For women with a previously affected infant, ACR conditionally recommends weekly fetal echocardiography during the same period. ^[2]

The recommendation is conditional because the evidence is limited.

SMFM Approach

SMFM recommends that serial fetal echocardiograms for routine PR-interval assessment should not be performed routinely outside a clinical-trial setting in anti-SSA/SSB-positive pregnancies.

SMFM cites uncertainty that intensive PR-interval screening improves outcomes and concern about interventions prompted by unproven surrogate findings. ^[1]

Dr Tania’s Clinical Interpretation

The two recommendations reflect uncertainty in the evidence—not a disagreement that congenital heart block matters.

The individual plan should consider:

Previous affected child.
Antibody profile.
Local fetal-cardiology expertise.
Availability and quality of fetal echocardiography.
Maternal hydroxychloroquine use.
The woman’s values after counselling.
Whether a clinical trial or specialist protocol is available.
Whether fetal bradycardia or another cardiac concern is detected.

The surveillance plan should be explicit about which guideline framework is being followed and why.

Routine Obstetric Heart-Rate Assessment Still Matters

Even when serial PR-interval echocardiography is not planned, routine obstetric care should document the fetal heart rate.

Persistent fetal bradycardia, rhythm irregularity or another concern requires prompt specialist assessment.

A normal handheld Doppler reading at home does not replace:

Professional fetal-heart assessment.
Fetal echocardiography when indicated.
Structural ultrasound.
Maternal–fetal medicine review.

Home Heart-Rate Monitoring Is Not a Proven Substitute

Some families ask about frequent home Doppler or home rhythm monitoring.

Potential problems include:

False reassurance.
Difficulty identifying the maternal rather than fetal pulse.
Anxiety from normal variation.
Failure to recognise subtle conduction change.
Delayed professional assessment.
Unclear action thresholds.

Home monitoring should not be introduced without a specialist protocol, training and a clear response plan.

Hydroxychloroquine Should Generally Continue

ACR conditionally recommends hydroxychloroquine during pregnancy for women who are anti-Ro/SSA and/or anti-La/SSB positive. ^[2]

For women with SLE, hydroxychloroquine is also important for maternal disease control.

It should not be stopped because the antibodies are present.

Hydroxychloroquine and Recurrence Prevention

In the prospective PATCH study, anti-Ro/SSA-positive women with a previous pregnancy affected by congenital heart block received hydroxychloroquine early in pregnancy.

Cardiac neonatal lupus occurred in 7.4% of evaluable pregnancies, compared with the historical recurrence rate of approximately 18%.

The study supports hydroxychloroquine as secondary prevention for women with a previously affected child. ^[8]

It does not prove that hydroxychloroquine prevents every recurrence.

The dose and timing belong in a rheumatology and maternal–fetal medicine plan.

Starting Hydroxychloroquine Late Is Not the Same as Preconception Treatment

Hydroxychloroquine has a slow onset and long tissue half-life.

Women at recurrent cardiac risk ideally require preconception or very early pregnancy planning.

An unplanned pregnancy should still prompt rapid specialist review.

A woman should not double doses or change treatment independently because she discovers an antibody result late.

Steroids Do Not Routinely Prevent Congenital Heart Block

Prednisone or prednisolone used for maternal SLE does not provide a proven method of preventing fetal heart block.

Fluorinated steroids such as dexamethasone cross the placenta more readily.

Their fetal-cardiac use remains controversial because of:

Limited evidence of benefit.
Maternal glucose and blood-pressure effects.
Infection risk.
Fetal growth concerns.
Reduced amniotic fluid.
Other maternal and fetal toxicity.

They should not be started preventively in every antibody-positive pregnancy.

ACR and SMFM Also Differ on Treatment of Early Block

ACR conditionally recommends dexamethasone for fetal first- or second-degree heart block detected on echocardiography and conditionally recommends against dexamethasone for isolated complete third-degree block without other cardiac inflammation. ^[2]

SMFM recommends that steroids should not be used routinely for fetal heart block related to anti-SSA/SSB antibodies because benefit is unproven and maternal and fetal risks are known. ^[1]

Any treatment decision requires:

Confirmation by fetal cardiology.
Definition of the degree of block.
Assessment of ventricular function.
Review for myocarditis or endocardial fibroelastosis.
Maternal risks.
Gestational age.
Transparent discussion of uncertainty.

A website cannot determine whether fetal steroid treatment is appropriate.

Complete Heart Block Is Usually Irreversible

Established complete congenital heart block usually reflects fibrosis of the conduction system.

Treatment may support:

Fetal function.
Associated inflammation.
Hydrops management.
Timing and place of birth.
Neonatal pacing preparation.

It usually does not restore normal atrioventricular conduction.

Counselling should be realistic without implying that every affected fetus has the same outcome.

Fetal Bradycardia Requires Prompt Confirmation

A persistently slow fetal heart rate may reflect:

Congenital heart block.
Sinus bradycardia.
Medication exposure.
Fetal compromise.
A rhythm measurement error.
Maternal pulse being recorded.
Another cardiac or fetal condition.

The next step is prompt professional assessment—not assumption.

Paediatric Cardiology Should Be Involved When Disease Is Suspected

When fetal conduction disease or cardiac inflammation is identified, planning may include:

Fetal cardiology.
Maternal–fetal medicine.
Rheumatology.
Neonatology.
Paediatric electrophysiology.
Delivery at a centre with appropriate neonatal cardiac support.
Postnatal electrocardiography and echocardiography.
Pacemaker planning when required.

The place of birth should match the anticipated neonatal need.

Non-Cardiac Neonatal Lupus Is Usually Temporary

Possible manifestations include:

Photosensitive rash.
Low platelets.
Low white blood cells.
Anaemia.
Elevated liver enzymes.

A prospective study found cutaneous, haematological and liver manifestations more commonly than congenital heart block. ^[11]

These findings often improve as maternal antibodies clear.

They still require paediatric assessment and follow-up.

The Rash May Appear After Birth

Neonatal lupus rash may not be visible immediately.

It may appear after ultraviolet-light exposure.

Parents may be advised about:

Sun protection.
Photographs of new lesions.
Paediatric review.
Blood-count or liver testing when indicated.
Expected resolution.
Differentiation from infection, eczema or another rash.

The child should not be labelled as having lifelong SLE from a transient antibody-mediated rash.

The Newborn Plan Should Be Written Before Delivery

For an antibody-positive pregnancy, the newborn plan may include:

Physical examination.
Heart-rate and rhythm assessment.
Electrocardiogram.
Echocardiogram when indicated.
Blood count.
Liver tests.
Skin review.
Feeding and general observation.
Paediatric follow-up.
Parent education about rash, jaundice, bruising, pallor or poor feeding.

The exact plan depends on:

Maternal antibodies.
Fetal findings.
Previous affected child.
Medicines.
Local paediatric protocol.

Maternal Antibody Positivity May Be Discovered Through the Baby

Some women have no previous symptoms of SLE or Sjögren’s syndrome.

Anti-Ro/SSA antibodies may first be identified after fetal or neonatal heart block or neonatal lupus.

The maternal plan should then include:

Rheumatology assessment.
Review for autoimmune symptoms.
Additional antibody and laboratory testing.
Long-term follow-up.
Counselling before another pregnancy.

The mother should not be told automatically that she has SLE solely because the antibody is present.

Future Pregnancy Counselling Is Essential

After an affected pregnancy, retain:

Maternal antibody reports.
Fetal echocardiograms.
Fetal-cardiology notes.
Delivery record.
Neonatal electrocardiogram and echocardiogram.
Pacemaker or cardiology records.
Skin photographs.
Blood-count and liver results.
Hydroxychloroquine timing and dose.
Other fetal treatments.

These records determine recurrence counselling and future preventive planning.

Anti-Ro/SSA and anti-La/SSB positivity creates a small but important fetal risk. The correct response is precise counselling, appropriate maternal treatment and a transparent fetal-cardiac plan—not prediction that the baby will be affected.

Maternal & Fetal Surveillance

Maternal and Fetal Surveillance

Surveillance in SLE should be individualised according to:

Disease activity.
Previous organ involvement.
Lupus nephritis.
Kidney function.
Blood pressure.
Antiphospholipid antibodies or APS.
Anti-Ro/SSA and anti-La/SSB status.
Medication.
Previous pregnancy outcome.
Current fetal growth.
Placental findings.
Gestational age.

A fixed schedule copied from another woman may be either insufficient or unnecessarily intensive.

The Care Team Should Be Defined

The core team commonly includes:

Obstetric or maternal–fetal medicine care.
Rheumatology.

Additional specialists may include:

Nephrology.
Haematology.
Cardiology.
Pulmonary-hypertension specialists.
Neurology.
Fetal cardiology.
Neonatology.
Anaesthesia.
Other organ specialists.

Not every woman requires every service.

The team should reflect her actual disease.

Visits Should Have a Defined Purpose

Each review should ask:

Has lupus activity changed?
Has blood pressure changed?
Has kidney function changed?
Has proteinuria changed?
Is infection present?
Are medicines being taken and tolerated?
Is thrombosis or bleeding risk changing?
Is fetal growth appropriate?
Are fetal movements normal?
Does the surveillance or delivery plan need revision?

A visit should not become a repeated list of normal results without an action framework.

Maternal Symptom Review

At each clinically appropriate review, ask about:

Rash.
Mouth or nasal ulcers.
Joint swelling.
Pleuritic or pericardial pain.
Fever.
Urinary symptoms.
Foamy or bloody urine.
Reduced urine output.
Headache.
Visual disturbance.
Upper-abdominal pain.
Breathlessness.
Chest pain.
One-sided leg swelling.
Neurological symptoms.
Bleeding.
Medication adverse effects.
Fetal movements.

The woman should know which symptoms require same-day or emergency assessment.

Blood Pressure Requires Ongoing Attention

Blood pressure should be assessed with:

Correct cuff size.
Appropriate positioning.
Repeat measurement when elevated.
Comparison with baseline.
Home monitoring when clinically useful.
Review of the device and technique.
A written threshold for contacting the clinical team.

Hypertension may indicate:

Chronic hypertension.
Lupus nephritis.
Preeclampsia.
Medication effect.
Pain or acute illness.
More than one process.

A single normal result does not guarantee that hypertensive disease will not develop later.

Laboratory Monitoring Should Follow Disease Risk

Maternal monitoring may include:

Full blood count.
Creatinine.
Electrolytes.
Liver tests.
Urinalysis.
Quantified urine protein.
Urinary sediment.
Complement.
Anti-double-stranded DNA antibodies.
Serum albumin.
Glucose.
Medication-specific tests.
Other investigations guided by symptoms.

ACR supports clinical and laboratory assessment of SLE activity at least once per trimester. ^[2]

Women with nephritis, hypertension, active disease, medication change or abnormal results usually require more frequent monitoring.

Stable Results Are Still Compared With the Baseline

The meaning of a result depends on:

Pre-pregnancy value.
Early-pregnancy value.
Trend.
Gestational age.
Disease activity.
Medication.
Maternal symptoms.

Examples include:

Creatinine that remains within a non-pregnant range but has risen from the pregnancy baseline.
Complement that remains within the laboratory range but has fallen substantially.
Proteinuria that is high but unchanged from old renal damage.
Platelets that are low but stable for the woman.

Trend-based care prevents both overreaction and missed deterioration.

Lupus Nephritis Requires Closer Renal Surveillance

Monitoring may include:

Blood pressure.
Creatinine.
Urine protein.
Urinary sediment.
Serum albumin.
Complement.
Anti-double-stranded DNA.
Medication levels when relevant.
Oedema and urine output.
Fetal growth and placental assessment.

The frequency depends on:

Remission status.
Baseline kidney function.
Proteinuria.
Hypertension.
Previous flare severity.
Current trend.

A woman with active nephritis should not be managed through routine low-risk pregnancy visits.

Medication Surveillance Is Part of Disease Surveillance

Review should include:

Hydroxychloroquine adherence.
Steroid dose.
Immunosuppressive medicine.
Aspirin.
Heparin or another anticoagulant.
Antihypertensive treatment.
Adverse effects.
Laboratory monitoring.
Prescription supply.
Vomiting or missed doses.
Interacting medicines.

A disease flare may begin after an unrecognised interruption in treatment.

Infection Surveillance Must Remain Active

Immunosuppression may alter infection presentation.

The woman should report:

Fever.
Respiratory symptoms.
Urinary symptoms.
Diarrhoea.
Skin infection.
Dental infection.
Exposure to serious infection.
Reduced fetal movements during illness.

Infection may mimic or trigger flare.

It should be assessed before immunosuppression is escalated when clinically possible.

Early Pregnancy Ultrasound

Early ultrasound establishes:

Viability.
Number of fetuses.
Chorionicity in multiple pregnancy.
Accurate gestational age.
Early structural information when assessable.

Reliable dating is essential for:

Fetal-growth interpretation.
Preterm-birth decisions.
Surveillance.
Delivery timing.

Aneuploidy Screening and Diagnostic Testing

SLE does not automatically change the available genetic-screening and diagnostic-testing options.

The discussion should consider:

Maternal age.
Previous pregnancy.
Ultrasound findings.
Cell-free DNA or serum screening.
Diagnostic testing.
Medication exposure.
Anticoagulation.
The woman’s preferences.

Anticoagulation may require procedural planning for invasive testing.

Detailed Fetal Anatomy

A detailed structural ultrasound should assess routine fetal anatomy.

Additional focus may be influenced by:

Medication exposure.
Diabetes.
Anti-Ro/SSA or anti-La/SSB antibodies.
Previous fetal abnormality.
Screening results.
Maternal organ disease.

A normal anatomy scan is reassuring.

It does not assess future placental function or guarantee that immune-mediated rhythm disease will not develop later.

Serial Fetal Growth

SMFM recommends serial growth ultrasound in pregnant patients with SLE because of increased risk of fetal growth restriction and stillbirth. ^[1]

Growth assessment should review:

Estimated fetal weight.
Abdominal circumference.
Growth velocity.
Amniotic fluid.
Placental appearance.
Doppler when indicated.

The interval should be long enough to assess meaningful growth.

Repeating fetal weight too frequently can create misleading centile changes from measurement variation.

Fetal Growth Restriction Changes the Plan

When estimated fetal weight or abdominal circumference is below the 10th percentile, or growth velocity is concerning, review should include:

Dating.
Umbilical-artery Doppler.
Amniotic fluid.
Maternal blood pressure.
Preeclampsia assessment.
APS and placental risk.
Disease activity.
Surveillance.
Delivery planning.

The pregnancy should then follow an appropriate fetal-growth-restriction framework rather than routine SLE surveillance alone.

Umbilical-Artery Doppler

Umbilical-artery Doppler is particularly important when:

Fetal growth restriction is present.
Placental insufficiency is suspected.
Hypertension or preeclampsia is present.
APS-related placental disease is suspected.

The report should specify:

Vessel assessed.
Resistance measurement.
Presence of end-diastolic flow.
Absent or reversed flow.
Gestational-age interpretation.

A normal Doppler is reassuring.

It does not guarantee that placental function will remain normal.

Additional Doppler Studies

Selected cases may include:

Middle-cerebral-artery Doppler.
Cerebroplacental ratio.
Uterine-artery Doppler.
Ductus-venosus Doppler.

These studies answer different questions.

They should not be combined into one vague statement that “all Dopplers are normal.”

Their role depends on fetal growth, anaemia risk, gestational age and specialist protocol.

Amniotic Fluid

Amniotic-fluid assessment may help identify:

Placental insufficiency.
Fetal growth restriction.
Fetal kidney or urinary concerns.
Ruptured membranes.
Medication effects.
Another pregnancy complication.

Low fluid in an SLE pregnancy should not automatically be attributed to lupus.

The complete cause should be assessed.

Antenatal Fetal Surveillance

SMFM recommends antenatal testing in SLE because of increased risk of fetal growth restriction and stillbirth. ^[1]

Testing may include:

Nonstress testing or CTG.
Biophysical profile.
Modified biophysical profile.
Amniotic-fluid assessment.
Other surveillance according to local practice.

SMFM does not prescribe one identical start date or frequency for every SLE pregnancy.

The schedule should reflect:

Disease activity.
Nephritis.
Hypertension.
APS.
Fetal growth.
Medication.
Previous stillbirth or placental disease.
Current maternal and fetal findings.

A Reassuring Test Has Limits

A reactive nonstress test or reassuring biophysical profile means that no concerning abnormality was identified during that assessment.

It does not:

Guarantee safety until the next appointment.
Exclude future placental deterioration.
Replace fetal-movement awareness.
Measure maternal lupus activity.
Replace growth ultrasound.
Remove the need for blood-pressure and renal monitoring.

Surveillance provides information.

It does not create certainty.

Fetal-Movement Awareness

The woman should know her baby’s usual movement pattern.

She should seek prompt maternity assessment for:

Reduced movements.
Absent movements.
A clear change in pattern.
Concern that something is wrong.

She should not wait for:

The next lupus appointment.
The next ultrasound.
The next CTG.
The planned delivery date.
A home Doppler result.

Scheduled surveillance should never be used to dismiss a change occurring between appointments.

Surveillance for APS-Related Placental Disease

Women with APS or a high-risk antiphospholipid-antibody profile may require closer review of:

Maternal thrombosis symptoms.
Blood pressure.
Platelets.
Fetal growth.
Amniotic fluid.
Doppler.
Antenatal testing.
Placental complications.
Anticoagulant adherence and bleeding.

Stable lupus activity does not remove APS-related placental risk.

Anti-Ro/SSA and Anti-La/SSB Surveillance Is Separate

The fetal-cardiac plan should be documented separately from:

Growth scans.
CTG.
Biophysical profiles.
APS surveillance.

A normal fetal echocardiogram does not assess placental growth.

A normal growth scan does not assess subtle conduction disease.

Each test should answer its own clinical question.

Maternal Cardiac and Pulmonary Surveillance

Women with previous or current cardiac or pulmonary involvement may require:

Clinical review.
Oxygen saturation.
Electrocardiogram.
Echocardiography.
Pulmonary testing.
Biomarkers.
Additional imaging.
Anaesthetic review.
Specialist follow-up.

The schedule depends on:

Pulmonary hypertension.
Cardiomyopathy.
Valvular disease.
Previous myocarditis.
Previous pulmonary embolism.
Current symptoms.

New chest pain, significant breathlessness, fainting or reduced exercise tolerance requires prompt assessment.

Neurological Surveillance

Women with previous neurological lupus, stroke, seizure or APS-related neurological disease require a written plan for:

Medication.
Recurrence symptoms.
Blood pressure.
Anticoagulation.
Imaging when required.
Neurology review.
Anaesthesia.
Postpartum risk.

A new severe headache or neurological symptom should not be managed through routine outpatient follow-up.

Anaesthetic Review Before Birth

Early anaesthetic review may be useful when there is:

Therapeutic anticoagulation.
Thrombocytopenia.
Previous spinal disease.
Severe obesity.
Cardiopulmonary disease.
Kidney disease.
Long-term steroid treatment.
Previous difficult airway or anaesthetic complication.
Planned high-risk delivery.

The review can clarify:

Neuraxial options.
Anticoagulant timing.
Platelet concerns.
Stress-dose steroid assessment.
Monitoring.
Postoperative care.

Hospital Admission Is Not Required for Every Woman

Outpatient care may be appropriate when:

Disease is stable.
Blood pressure is controlled.
Kidney function is stable.
Fetal growth is reassuring.
Surveillance is reassuring.
Medication is established.
Follow-up is reliable.
The woman can access urgent maternity care.

Admission may be required for:

Severe flare.
Active nephritis.
Severe hypertension.
Preeclampsia.
Thrombosis.
Significant bleeding.
Serious infection.
Maternal organ dysfunction.
Abnormal fetal surveillance.
Severe fetal growth restriction.
Another maternal or fetal concern.

Every Surveillance Plan Needs an Escalation Path

The written plan should state:

Which maternal tests are being followed.
Which fetal tests are being used.
How often review occurs.
Which symptoms require same-day assessment.
Which result requires hospital admission.
Which result requires medication change.
Which result requires delivery.
Which specialists must be contacted.
The provisional birth window.
The postpartum follow-up plan.

Surveillance is useful only when an abnormal result changes care and a reassuring result is understood as temporary information—not a guarantee.

The next part will explain timing and mode of birth, labour preparation, anticoagulation and anaesthesia, postpartum flare and thrombosis risk, medication continuation and breastfeeding.

Timing & Mode of Birth

Timing and Mode of Birth

SLE does not create one automatic delivery date.

The birth plan should respond to:

Maternal disease activity.
Organ involvement.
Kidney function.
Blood pressure.
Preeclampsia.
Antiphospholipid syndrome.
Thrombosis or bleeding.
Fetal growth.
Doppler findings.
Antenatal surveillance.
Medication.
Anticoagulation.
Previous birth history.
Gestational age.
The woman’s preferences.

A stable woman with quiet disease and a normally growing fetus does not require preterm birth simply because she has SLE.

A woman with active organ disease, placental dysfunction or maternal deterioration may require earlier delivery.

There Is No Single Universal Gestational-Age Rule

Current SLE guidance recommends serial growth assessment and antenatal surveillance because placental complications and stillbirth risk are increased.

It does not prescribe one identical delivery week for every woman with lupus. ^[1]

The provisional birth window should be discussed during pregnancy and revised when new information appears.

The plan may change because of:

Preeclampsia.
Severe hypertension.
Lupus nephritis.
Maternal organ dysfunction.
Fetal growth restriction.
Abnormal Doppler.
Reduced amniotic fluid.
Non-reassuring fetal surveillance.
Thrombosis.
Bleeding.
Ruptured membranes.
Labour.
Infection.
Another obstetric indication.

Stable SLE Can Often Continue to Term

When:

Lupus is quiet.
Blood pressure is controlled.
Kidney function is stable.
There is no severe maternal organ disease.
Fetal growth is appropriate.
Antenatal surveillance is reassuring.
No other obstetric indication is present.

continuing pregnancy to a planned term birth may be appropriate.

“Term” still includes more than one gestational week.

The exact plan should balance:

Continuing fetal maturity.
Placental risk.
Maternal disease.
Anticoagulation coordination.
Local induction practice.
Cervical status.
Distance from specialist care.
Maternal preference.

A reassuring assessment today does not guarantee that the original birth date will remain appropriate.

Active Lupus Does Not Automatically Mean Immediate Delivery

A lupus flare may require:

Pregnancy-compatible immunosuppression.
Hospital care.
Nephrology, rheumatology or another organ specialist.
Maternal and fetal monitoring.
Treatment of infection when present.

Delivery is not the primary treatment for autoimmune inflammation.

When maternal and fetal conditions are stable, treating the flare and continuing pregnancy may be appropriate.

Delivery may become necessary when:

Maternal organ function is deteriorating.
Treatment cannot control life-threatening disease.
Severe preeclampsia is present.
Fetal condition is concerning.
Gestational age and the total risk favour birth.
Another obstetric emergency occurs.

Lupus Nephritis Requires Diagnosis-Specific Planning

Active lupus nephritis and preeclampsia can overlap.

The birth decision should consider:

Gestational age.
Creatinine trend.
Urine output.
Proteinuria.
Urinary sediment.
Complement and anti-double-stranded DNA trends.
Blood pressure.
Platelets.
Liver tests.
Maternal symptoms.
Fetal growth.
Doppler.
Antenatal surveillance.
Response to treatment.
Whether both nephritis and preeclampsia are present.

Delivery treats placental disease.

It does not cure active lupus nephritis.

Renal treatment and follow-up must continue after birth. ^[5]

Preeclampsia May Require Earlier Birth

When preeclampsia develops, timing follows:

Gestational age.
Severe features.
Blood-pressure control.
Maternal laboratory results.
Neurological or respiratory symptoms.
Fetal growth.
Fetal surveillance.
Maternal and fetal stability.
Current obstetric guidance.

SLE does not create a reason to delay delivery when severe preeclampsia requires birth.

It also does not mean that every rise in proteinuria should be treated as preeclampsia.

Fetal Growth Restriction Changes the Delivery Framework

When fetal growth restriction is present, timing depends on:

Estimated fetal weight.
Abdominal circumference.
Growth velocity.
Umbilical-artery Doppler.
Other Doppler findings when used.
Amniotic fluid.
Antenatal testing.
Preeclampsia.
APS.
Maternal disease.
Gestational age.

The pregnancy should follow an evidence-based fetal-growth-restriction pathway.

The diagnosis of SLE should not replace interpretation of the fetal and placental findings.

APS Does Not Create One Automatic Delivery Week

APS may increase the risk of:

Preeclampsia.
Placental insufficiency.
Fetal growth restriction.
Thrombosis.
Pregnancy loss.
Preterm birth.

Birth timing should respond to the complication that is present.

A woman with stable obstetric APS, reassuring fetal growth and no maternal complication may have a very different plan from a woman with:

Severe preeclampsia.
Abnormal Doppler.
Previous thrombosis.
Therapeutic anticoagulation.
Falling platelets.
Recurrent bleeding.

Anticoagulation coordination may support a planned birth.

It does not automatically require preterm birth or caesarean delivery.

Anti-Ro/SSA or Anti-La/SSB Positivity Alone Does Not Require Early Birth

When fetal rhythm, heart function, growth and surveillance are reassuring, maternal antibody positivity alone does not create an automatic indication for preterm delivery.

If fetal cardiac disease is present, timing and place of birth should be planned with:

Fetal cardiology.
Maternal–fetal medicine.
Neonatology.
Paediatric electrophysiology when required.

The decision should reflect:

Fetal heart rate.
Ventricular function.
Hydrops.
Associated cardiac inflammation.
Gestational age.
Expected neonatal need.

Congenital Heart Block Does Not Automatically Require Caesarean Birth

A fetus with complete heart block may be difficult to monitor using conventional electronic fetal-heart-rate interpretation.

The birth plan may require:

Specialist ultrasound assessment.
Alternative intrapartum monitoring strategies.
A centre with neonatal cardiac support.
Individualised timing.
A clear threshold for operative birth.

The rhythm diagnosis alone does not prove that labour is unsafe.

The full fetal cardiac and obstetric picture matters.

Reduced Fetal Movements Require Assessment Before the Planned Date

A planned induction or caesarean date should never be used to dismiss:

Reduced movements.
Absent movements.
Vaginal bleeding.
Fluid leakage.
Severe maternal symptoms.
A clear change in wellbeing.

The pregnancy must be reassessed when the clinical picture changes.

Antenatal Corticosteroids May Be Used When Preterm Birth Is Expected

When medically indicated preterm birth is likely, antenatal corticosteroids may be recommended according to:

Gestational age.
Timing of expected birth.
Previous course.
Maternal diabetes.
Current obstetric guidance.

Steroids given for fetal maturation are different from steroids used to treat maternal lupus.

The maternal glucose plan may need adjustment.

Urgent delivery should not be delayed merely to complete a steroid course when maternal or fetal danger requires birth.

Magnesium Sulfate Is Used for Obstetric Indications

Magnesium sulfate may be recommended for:

Seizure prevention or treatment in preeclampsia or eclampsia.
Fetal neuroprotection before selected early preterm births.

It is not a treatment for lupus activity.

Kidney impairment may change dosing and monitoring because magnesium is cleared through the kidneys.

The team should review:

Kidney function.
Reflexes.
Respiratory status.
Urine output.
Serum levels when clinically indicated.

Vaginal Birth Is Often Appropriate

SLE alone is not an indication for caesarean delivery.

Vaginal birth may be appropriate when:

Maternal condition is stable.
Fetal condition is reassuring.
There is no obstetric contraindication.
Labour can be monitored safely.
Anticoagulation and anaesthesia have been coordinated.

Possible benefits include:

Less surgical blood loss.
Lower wound risk.
Earlier mobility.
Lower postoperative thrombosis burden.
Faster physical recovery.

These benefits do not override a genuine obstetric or maternal indication for caesarean birth.

Induction of Labour May Be Appropriate

Induction may be offered because of:

Planned term birth.
Preeclampsia.
Fetal growth restriction.
Placental risk.
Maternal disease.
Ruptured membranes.
Anticoagulation coordination.
Another obstetric indication.

The likelihood of vaginal birth depends on:

Cervical status.
Parity.
Previous birth history.
Fetal position.
Gestational age.
Induction method.
Maternal and fetal tolerance of labour.

Induction is not proof that the body has failed.

It is one way to manage the balance between continuing pregnancy and planned birth.

Caesarean Birth Should Follow a Defined Indication

Possible indications include:

Placenta previa.
Certain previous uterine surgery.
Persistent non-reassuring fetal status.
Failed induction.
Labour obstruction.
Malpresentation.
Severe maternal instability.
A fetal cardiac or other condition for which the specialist team recommends operative delivery.
Another accepted obstetric reason.

SLE, hydroxychloroquine use, anti-Ro/SSA positivity or APS alone does not automatically require caesarean birth.

Previous Caesarean Birth Requires Individual Review

The discussion should include:

Number of previous caesareans.
Type of uterine incision.
Previous vaginal birth.
Reason for the previous caesarean.
Placental location.
Current fetal presentation.
Maternal disease.
Anticoagulation.
Induction options.
Local emergency capability.
The woman’s preferences.

A trial of labour after caesarean may be appropriate for selected women.

The decision should follow obstetric safety principles rather than the lupus diagnosis alone.

Anticoagulation Must Be Coordinated With the Birth Plan

The plan should state:

Which anticoagulant is being used.
Whether treatment is prophylactic or therapeutic.
The last planned dose.
What to do if labour begins.
What to do if the membranes rupture.
Whether conversion to another heparin preparation is planned.
Which anaesthetic options may be available.
When treatment restarts postpartum.
Which clinician can be contacted urgently.

The woman should not independently skip several doses to make an epidural possible.

Missing anticoagulation may create thrombosis risk.

Taking a recent dose may restrict neuraxial anaesthesia or increase procedural bleeding.

The balance requires a written specialist plan.

Planned Birth Can Support Neuraxial Anaesthesia

A planned induction or caesarean may help coordinate the interval between the last heparin dose and:

Epidural analgesia.
Spinal anaesthesia.
Surgery.

The required interval depends on:

Low-molecular-weight or unfractionated heparin.
Prophylactic or therapeutic intensity.
Kidney function.
Platelet count.
Bleeding risk.
Anaesthetic guidance.

A planned date improves coordination.

It does not guarantee that labour or an emergency will not occur earlier.

Platelets Affect Anaesthetic and Bleeding Planning

Thrombocytopenia may be caused by:

SLE.
Immune thrombocytopenia.
APS.
Preeclampsia or HELLP syndrome.
Heparin-induced thrombocytopenia.
Medication.
Infection.
Gestational thrombocytopenia.
Another disorder.

The anaesthetic decision considers:

Platelet count.
Trend.
Cause.
Bleeding history.
Anticoagulation.
Other coagulation results.
Urgency.
Local guidance.

There is no single website number that safely decides epidural suitability for every woman.

Long-Term Steroid Use Should Be Reviewed Before Labour

The plan should document:

Current glucocorticoid.
Dose.
Duration.
Recent high-dose courses.
Adrenal-suppression concern.
Whether supplementary steroid is required for labour or surgery.
Glucose monitoring.
Infection and wound considerations.

ACR’s reproductive-health guidance distinguishes vaginal birth from caesarean surgery when considering stress-dose glucocorticoids, but the final decision should be individualised to the woman’s exposure and clinical stress. ^[2]

A woman should not be given or denied supplementary steroid solely because she carries an SLE diagnosis.

Maternal Medicines Should Be Reconciled Before Admission

The birth record should clearly state which medicines continue around labour, including:

Hydroxychloroquine.
Glucocorticoids.
Azathioprine.
Tacrolimus or ciclosporin.
Antihypertensive medicines.
Aspirin.
Heparin or another anticoagulant.
Other prescribed treatment.

Hospital admission should not create an accidental interruption in disease-controlling medication.

Blood Products and Bleeding Planning

Additional planning may be required when there is:

Anaemia.
Thrombocytopenia.
Anticoagulation.
Placenta previa or accreta risk.
Previous postpartum haemorrhage.
Kidney or liver dysfunction.
Autoimmune haemolysis.
Antibodies complicating blood matching.
Planned caesarean birth.

The plan may include:

Current blood count.
Blood group and antibody screen.
Cross-matching.
Haematology advice.
Cell-salvage planning where appropriate.
Postpartum anticoagulant restart criteria.

Place of Birth Should Match the Risk

Birth at a specialist centre may be appropriate for:

Active lupus nephritis.
Severe kidney impairment.
Pulmonary hypertension.
Significant cardiac disease.
Therapeutic anticoagulation.
Previous major thrombosis.
Severe hypertension or preeclampsia.
Significant thrombocytopenia.
Severe fetal growth restriction.
Congenital heart block or fetal cardiac dysfunction.
Expected preterm birth.
Need for neonatal intensive care.

A stable woman with lower-risk disease may not require the highest-level unit.

The setting should match the expected maternal and neonatal need.

The Birth Plan Must Include Contingencies

A useful plan should answer:

What is the provisional birth window?
What findings would bring birth forward?
Is induction expected?
Is vaginal birth appropriate?
What would require caesarean birth?
What happens to aspirin?
What happens to heparin?
Is neuraxial analgesia likely to be available?
Is supplementary steroid required?
Which maternal monitoring is needed?
Which newborn team should attend?
When do lupus medicines restart?
When does anticoagulation restart?
Who reviews the mother postpartum?

The birth plan should be specific enough to coordinate lupus, placental, anticoagulation, anaesthetic and newborn care—and flexible enough to change when the mother or baby changes.

Labour, Postpartum & Breastfeeding

Labour, Postpartum and Breastfeeding

Birth is not the end of high-risk lupus care.

Labour and the postpartum period may involve:

Fluid shifts.
Blood-pressure change.
Bleeding.
Infection.
Surgery.
Medication interruption.
Increased thrombosis risk.
Sleep deprivation.
Lupus flare.
Kidney deterioration.
Breastfeeding questions.
Newborn assessment.

The postpartum plan should be written before delivery.

Assessment on Admission in Labour

The maternity team should know:

SLE manifestations.
Current disease activity.
Previous severe organ involvement.
Kidney function.
Baseline and current proteinuria.
Blood pressure.
Platelet count.
Antiphospholipid-antibody and APS status.
Previous thrombosis.
Anti-Ro/SSA and anti-La/SSB status.
Fetal cardiac findings.
Current medicines.
Last aspirin dose.
Last anticoagulant dose.
Steroid exposure.
Anaesthetic plan.
Newborn plan.

The woman should not have to reconstruct a complex medical history during painful contractions or an emergency.

Continue Essential Disease-Control Treatment

Hydroxychloroquine and other pregnancy-compatible maintenance medicines should not be omitted without a clinical reason.

Potential interruptions include:

Nil-by-mouth instructions.
Vomiting.
Transfer between wards.
Surgery.
Prescription reconciliation errors.
Uncertainty about breastfeeding.
Lack of medicine supply.

The team should decide:

Which oral medicines continue.
Which medicines require another route.
Which doses are delayed.
When normal administration resumes.

A short hospital admission can still create a clinically important medication gap.

Fluid Management Must Be Individualised

Labour, intravenous treatment and surgery can change fluid balance.

The plan should consider:

Kidney function.
Urine output.
Proteinuria.
Serum albumin.
Blood pressure.
Preeclampsia.
Cardiac disease.
Pulmonary hypertension.
Pulmonary oedema risk.
Blood loss.
Infection.
Oral intake.

A woman with kidney or cardiac disease should not receive a routine large fluid load without reassessment.

Fluid restriction should also not create dehydration, hypotension or kidney injury.

Pain Relief Should Be Planned

Options may include:

Non-pharmacological support.
Inhaled analgesia.
Opioid analgesia.
Epidural analgesia.
Spinal or combined spinal–epidural techniques.
General anaesthesia when required.

The choice may be affected by:

Anticoagulation.
Platelet count.
Infection.
Spine or neurological disease.
Cardiopulmonary disease.
Urgency.
Maternal preference.

SLE itself does not automatically prevent epidural analgesia.

Neuraxial Analgesia Depends on Anticoagulation Timing

Epidural or spinal procedures require safe coordination with heparin.

The anaesthetic team should confirm:

Last dose.
Heparin type.
Dose category.
Kidney function.
Platelet count.
Bleeding risk.
Planned catheter removal.
Postpartum anticoagulant restart.

The same timing issue applies when removing an epidural catheter.

Restarting anticoagulation too early may increase spinal bleeding risk.

Delaying it unnecessarily may increase thrombosis risk.

Continuous Fetal Monitoring May Be Recommended

Continuous CTG may be recommended when there is:

Induction.
Fetal growth restriction.
Preeclampsia.
Abnormal Doppler.
APS-related placental concern.
Oxytocin.
Meconium.
Epidural analgesia according to local practice.
Another obstetric indication.

Stable SLE alone does not mean that every labour must be managed identically.

The intrapartum plan should follow the current maternal and fetal risk.

Fetal Heart Block Requires a Specialist Monitoring Plan

Conventional CTG interpretation may be difficult when the fetal baseline heart rate is persistently slow because of complete heart block.

The plan may involve:

Intermittent or continuous ultrasound assessment.
Review of ventricular function.
Maternal contraction and fetal response assessment.
A predefined threshold for operative birth.
Fetal cardiology input.
Neonatal cardiac attendance.

The team should not first discover this monitoring difficulty after labour begins.

Fever in Labour Requires Assessment

Fever may reflect:

Intra-amniotic infection.
Urinary infection.
Respiratory or other infection.
Epidural-associated temperature rise.
Lupus activity.
Another cause.

The response may include:

Maternal observations.
Cultures.
Antibiotics.
Fetal assessment.
Lupus review.
Delivery decisions.

Fever should not automatically be labelled a flare.

Hypertension in Labour Requires Prompt Treatment

Severe hypertension may cause:

Stroke.
Seizure.
Cardiac or kidney complications.
Placental abruption.
Fetal compromise.

Management may include:

Repeated confirmation.
Urgent antihypertensive treatment.
Preeclampsia assessment.
Magnesium sulfate when indicated.
Fluid review.
Delivery planning.

The presence of chronic hypertension or lupus nephritis does not make severe intrapartum blood pressure acceptable.

Caesarean Birth Requires Thrombosis and Infection Prevention

When caesarean birth is required, the plan may include:

Antibiotic prophylaxis.
Mechanical thromboprophylaxis.
Early mobilisation.
Anticoagulant restart.
Wound monitoring.
Glucose control.
Steroid planning.
Fluid balance.
Blood-pressure monitoring.
Pain management compatible with kidney and bleeding risk.

Immunosuppression may increase concern about infection and healing.

It does not mean that necessary surgery should be avoided.

Postpartum Haemorrhage and Anticoagulation Require Coordination

After significant bleeding, the team must balance:

Haemorrhage control.
Anaemia.
Surgical or procedural findings.
Ongoing bleeding risk.
Previous thrombosis.
APS.
Mode of birth.
Mobility.
Timing of anticoagulation restart.

The postpartum anticoagulant plan may need temporary revision.

It should not be abandoned without a documented reassessment.

The Postpartum Period Has High Thrombosis Risk

Thrombosis risk may be increased by:

APS.
Previous thrombosis.
Caesarean birth.
Immobility.
Infection.
Preeclampsia.
Postpartum haemorrhage.
Obesity.
Nephrotic syndrome.
Central venous access.
Dehydration.
Smoking or nicotine use.
Another thrombophilia.

Women with obstetric APS are commonly advised to continue prophylactic anticoagulation for six weeks postpartum, with some ACR guidance allowing six to twelve weeks according to the clinical situation. ^[2,7]

Women with thrombotic APS usually require therapeutic and often long-term anticoagulation.

The exact plan must be written.

Anticoagulation Restart Depends on Haemostasis

The restart time depends on:

Vaginal or caesarean birth.
Bleeding.
Surgical findings.
Epidural or spinal catheter.
Platelet count.
Kidney function.
Prophylactic or therapeutic intensity.
Thrombosis risk.
Anaesthetic guidance.

There is no one restart time that is safe for every woman.

Obstetric, anaesthetic and haematology teams should agree on the plan.

Postpartum Preeclampsia Can Begin After Birth

Seek urgent assessment for:

Severe headache.
Visual disturbance.
Upper-abdominal or epigastric pain.
Breathlessness.
Chest pain.
Rapid swelling.
Severe hypertension.
Seizure.
Confusion.
Feeling seriously unwell.

Normal blood pressure before discharge does not completely exclude later postpartum preeclampsia.

A home blood-pressure plan may be appropriate for selected women.

Lupus Activity May Increase Postpartum

The postpartum period can be associated with flare because of:

Immune and hormonal change.
Medication interruption.
Infection.
Sleep deprivation.
Physical stress.
Reduced adherence.
Delayed follow-up.

Possible flare symptoms include:

New rash.
Inflammatory joint swelling.
Mouth or nasal ulcers.
Serositis.
Fever after infection has been considered.
Blood-count change.
Rising proteinuria.
Active urinary sediment.
Kidney-function deterioration.
Neurological or other organ symptoms.

Postpartum symptoms should not all be attributed to exhaustion.

Postpartum Renal Review Is Essential

For women with previous or current lupus nephritis, review may include:

Blood pressure.
Creatinine.
Electrolytes.
Urinalysis.
Quantified urine protein.
Urinary sediment.
Serum albumin.
Complement.
Anti-double-stranded DNA.
Medication.
Oedema and urine output.

Proteinuria from preeclampsia may take time to improve.

Active nephritis requires continued treatment.

Persistent renal abnormality should not be ignored because the pregnancy has ended. ^[5]

The Timing of Rheumatology Follow-Up Should Be Written

The plan should specify:

Who reviews the mother.
How soon review occurs.
Which blood and urine tests are required.
Which symptoms require earlier contact.
How medicine supply is maintained.
Whether nephrology, haematology or cardiology review is also needed.

A routine appointment several months later may be too late for a woman with recent active disease or medication transition.

Medication Should Be Reconciled Before Discharge

The discharge list should state:

Hydroxychloroquine.
Glucocorticoid dose and taper.
Azathioprine.
Tacrolimus or ciclosporin.
Biologic treatment.
Antihypertensive medicine.
Aspirin.
Anticoagulant.
Pain medicines.
Gastric protection.
Supplements.
Medicines that remain prohibited.
Required laboratory monitoring.

The woman should know:

Which medicine treats lupus.
Which medicine prevents thrombosis.
Which medicine treats blood pressure.
Which medicine is compatible with breastfeeding.
Which medicine has been stopped and why.
Who will issue the next prescription.

Breastfeeding Is Often Possible

ACR recommends supporting breastfeeding when the woman wishes to breastfeed and maintaining maternal disease control with lactation-compatible medicines. ^[2]

Breastfeeding decisions should consider:

Maternal disease activity.
Medicine.
Infant gestational age.
Infant health.
Feeding preference.
Milk supply.
Maternal sleep and recovery.
Access to practical support.

A woman should not be pressured to breastfeed at the cost of uncontrolled disease, severe sleep deprivation or unsafe medication interruption.

Hydroxychloroquine Is Compatible With Breastfeeding

Hydroxychloroquine passes into breast milk in small amounts and is considered compatible with breastfeeding by major rheumatology guidance. ^[2,6]

Continuing it may protect maternal disease control.

The infant should still receive all ordinary paediatric care.

Maternal hydroxychloroquine does not treat or prevent malaria in the breastfeeding infant.

Azathioprine Is Generally Compatible With Breastfeeding

ACR conditionally and updated EULAR guidance support azathioprine during breastfeeding. ^[2,6]

The plan may consider:

Maternal dose.
Infant prematurity.
Exclusive or partial breastfeeding.
Maternal metabolism.
Other immunosuppressive medicines.
Paediatric monitoring when clinically indicated.

A necessary medicine should not be stopped automatically because the woman plans to breastfeed.

Tacrolimus and Ciclosporin Can Be Compatible

ACR and updated EULAR recommendations consider tacrolimus and ciclosporin compatible with breastfeeding. ^[2,6]

The plan should consider:

Maternal kidney function.
Maternal drug level.
Infant prematurity.
Other medicines.
Paediatric follow-up.
Infant drug level or laboratory testing when a specialist identifies concern.

The maternal dose should not be changed independently to reduce breast-milk exposure.

Glucocorticoids Are Generally Compatible

Prednisone, prednisolone and other appropriate non-fluorinated glucocorticoids are generally compatible with breastfeeding. ^[2,6]

Higher doses may require individual advice about:

Dose timing.
Maternal glucose and blood pressure.
Infection.
Milk supply.
Infant exposure.
Duration.

The answer should reflect the actual drug and dose rather than the word steroid alone.

Biologic Treatment Requires Drug-Specific Review

Updated EULAR recommendations consider biologic disease-modifying medicines compatible with breastfeeding because transfer of these large molecules into milk and infant absorption are generally low. ^[6]

The individual plan should still consider:

Exact biologic.
Evidence available.
Maternal disease severity.
Infant prematurity or illness.
Late-pregnancy exposure.
Infant infection risk.
Infant vaccination plan.
Paediatric advice.

Treatment should not be grouped into one vague category called “biologics.”

Some Medicines Should Not Be Used While Breastfeeding

ACR recommends against breastfeeding use of:

Mycophenolate.
Cyclophosphamide.
Leflunomide.
Thalidomide.

It conditionally recommends against methotrexate during breastfeeding. ^[2]

The postpartum plan should provide a compatible alternative when maternal disease requires treatment.

A woman should not restart a pregnancy-incompatible or lactation-incompatible medicine from an old prescription without checking the current plan.

Severe Maternal Disease May Require Treatment That Changes Feeding Plans

When organ-threatening lupus requires a medicine that is not compatible with breastfeeding, maternal treatment takes priority.

The team should explain:

Why the medicine is needed.
Whether breastfeeding must pause or stop.
Whether expressed milk can be stored or used.
Whether milk production can be maintained safely.
Whether a later return to breastfeeding is possible.
Safe infant-feeding alternatives.

This is not a maternal failure.

It is treatment of serious disease.

Heparin and Warfarin Are Compatible With Breastfeeding

Unfractionated heparin and low-molecular-weight heparin are compatible with breastfeeding.

Warfarin is also generally compatible.

Direct oral anticoagulants are generally avoided during breastfeeding because infant-safety evidence remains limited and differs by medicine.

The postpartum anticoagulant should follow:

APS diagnosis.
Previous thrombosis.
Long-term need.
Kidney function.
Bleeding.
Monitoring access.
Maternal preference.
Specialist guidance.

Pain Relief Should Match Kidney, Bleeding and Breastfeeding Risk

Postpartum pain treatment should consider:

Kidney function.
Blood pressure.
Preeclampsia.
Anticoagulation.
Platelet count.
Gastric risk.
Breastfeeding.
Other medicines.

NSAIDs may be appropriate for some women postpartum.

They may be unsuitable for another woman with:

Kidney impairment.
Uncontrolled hypertension.
Significant bleeding.
Particular gastrointestinal or medication risks.

Paracetamol and opioids also require dose and infant-safety review.

Pain should be treated without assuming one regimen fits every woman.

Infant Vaccination May Require Review After Selected Biologic Exposure

Significant late-pregnancy exposure to selected biologic medicines may leave measurable medicine in the infant after birth.

The paediatric team may need to review the timing of live vaccines.

This issue depends on:

Exact biologic.
Timing of the last maternal dose.
Degree of placental transfer.
Infant gestational age.
Local vaccine schedule.
Current recommendations.

Routine non-live vaccines should not be delayed without a paediatric reason.

Breast-milk exposure alone is usually different from substantial placental exposure during late pregnancy.

The Anti-Ro/SSA-Positive Newborn Requires a Defined Plan

The newborn plan may include:

Heart-rate and rhythm assessment.
Electrocardiogram.
Echocardiography when indicated.
Blood count.
Liver tests.
Skin assessment.
Paediatric follow-up.
Parent education.

Seek paediatric assessment for:

Slow heart rate.
Poor feeding.
Breathing difficulty.
Marked sleepiness.
Pallor.
Bruising.
Jaundice.
A new rash.

Most antibody-exposed infants do not develop neonatal lupus.

A Baby With Congenital Heart Block Needs Cardiac Follow-Up

The plan may include:

Neonatal monitoring.
Electrocardiography.
Echocardiography.
Paediatric electrophysiology.
Pacemaker assessment.
Feeding and growth review.
Parent education.
Long-term cardiology follow-up.

The need for pacing depends on:

Heart rate.
Symptoms.
Ventricular function.
Rhythm.
Associated cardiac disease.

Not every affected infant follows the same course.

Infection Precautions Must Be Proportionate

The family should receive clear advice when maternal or infant immunosuppression is relevant.

Precautions may include:

Hand hygiene.
Prompt review of maternal fever.
Prompt review of infant fever.
Vaccine planning.
Avoiding unnecessary exposure to serious infection.
Food safety for the mother.
Wound and breast assessment.
Safe medicine use.

The mother and baby should not be isolated from ordinary support without a clinical reason.

Sleep and Support Are Part of Disease Control

Severe sleep disruption may affect:

Medication adherence.
Pain.
Mood.
Blood pressure.
Glucose.
Fatigue.
Recognition of flare.
Ability to attend follow-up.

The practical plan may include:

Shared night care.
Expressed milk or mixed feeding when desired.
Family support.
Rest after hospital discharge.
Help with older children.
Early review for mood or anxiety symptoms.

A feeding plan should support both infant nutrition and maternal health.

Mental Health Requires Direct Attention

The postpartum period may involve:

Anxiety about flare.
Fear of thrombosis.
Traumatic birth.
Depression.
Intrusive thoughts.
Sleep deprivation.
Steroid-related mood effects.
Difficulty adapting to chronic-disease care and newborn care together.

Seek urgent help for:

Thoughts of self-harm.
Thoughts of harming the baby.
Severe agitation.
Confusion.
Hallucinations.
Inability to sleep for a prolonged period despite opportunity.
Feeling unable to keep the mother or baby safe.

Mental-health symptoms should not be dismissed as ordinary tiredness.

Contraception Should Be Planned Before Discharge

The choice should consider:

Antiphospholipid antibodies.
APS.
Previous thrombosis.
Disease activity.
Blood pressure.
Medication.
Breastfeeding.
Menstrual bleeding on anticoagulation.
Desire and timing for another pregnancy.

Estrogen-containing methods may be unsuitable for women with positive antiphospholipid antibodies, APS or major thrombosis risk. ^[1,2]

Highly effective reversible methods may be appropriate for many women.

The decision should respect the woman’s preferences and future reproductive plans.

The Interpregnancy Plan Begins Postpartum

Before another pregnancy, review:

Recovery from birth.
Disease activity.
Kidney function.
Blood pressure.
Proteinuria.
Antibody profile already documented.
Thrombosis or placental complications.
Medication compatibility.
Caesarean or uterine history.
Neonatal-lupus history.
Maternal cardiac or pulmonary status.
Contraception.
The recommended interval before conception.

A difficult pregnancy does not mean that recurrence is inevitable.

It does mean that the next pregnancy should begin with the previous records and a deliberate plan.

What to Retain After Birth

Keep copies of:

Delivery summary.
Operative report.
Anaesthetic record.
Placental histology.
Maternal laboratory trends.
Kidney and urine results.
Blood-pressure record.
Anticoagulation plan.
Thrombosis or bleeding records.
Lupus-flare treatment.
Discharge medication list.
Newborn examination.
ECG and echocardiogram when performed.
Neonatal blood-count and liver results.
Paediatric-cardiology records.
Breastfeeding and medicine plan.

These records may change future counselling.

Dr Tania’s Clinical Interpretation

I do not use the same birth and postpartum plan for:

Quiet SLE without organ disease.
Previous nephritis in remission.
Active lupus nephritis.
Chronic kidney impairment.
Severe hypertension or preeclampsia.
Antibody positivity without APS.
Obstetric APS on prophylactic heparin.
Thrombotic APS on therapeutic anticoagulation.
Anti-Ro/SSA positivity with a normal fetal heart.
A fetus with congenital heart block.
Significant thrombocytopenia.
Pulmonary hypertension.
A woman restarting a lactation-incompatible medicine.

The plan should protect:

Maternal organ function.
Placental and fetal wellbeing.
Safe anticoagulation.
Anaesthetic options.
Newborn assessment.
Disease control during breastfeeding.
Early detection of postpartum flare, preeclampsia, infection and thrombosis.

A safe lupus pregnancy does not finish at delivery. The birth, medication, anticoagulation, breastfeeding, newborn and postpartum-review plans must connect without a gap.

The final part will add the Frequently Asked Questions, closing consultation section, Medical Disclaimer, complete Evidence Base, structured data and full-page verification requirements.

Frequently Asked Questions

Consultation

A Lupus Pregnancy Plan Should Explain More Than the Diagnosis

A specialist consultation should help you understand:

Whether lupus is currently quiet, uncertain or active.
Which organs have been involved.
Whether kidney disease is active or represents previous damage.
Your blood-pressure and urine-protein baseline.
Which antibodies change pregnancy care.
Whether antiphospholipid syndrome is present.
What anti-Ro/SSA or anti-La/SSB means for the fetus.
Which medicines should continue.
Which medicines require replacement.
How lupus flare and preeclampsia will be distinguished.
How maternal and fetal surveillance will be organised.
The provisional birth, anticoagulation and anaesthetic plan.
Which medicines can continue during breastfeeding.
How postpartum flare, hypertension and thrombosis risk will be monitored.
What should prompt urgent assessment.

A lupus pregnancy deserves coordinated care that protects maternal disease control while recognising placental, antibody, medication and postpartum risks early—without treating every woman as though her lupus is identical.

Schedule an SLE Pregnancy Consultation Request Review of Your Lupus, Antibodies and Medicines

Medical Disclaimer

This page provides general educational information about systemic lupus erythematosus in pregnancy. It does not diagnose lupus, determine disease activity, distinguish lupus nephritis from preeclampsia, prescribe medication, assess fetal wellbeing or replace personalised care from obstetric, maternal–fetal medicine, rheumatology, nephrology, haematology, cardiology, fetal-cardiology, anaesthetic or paediatric teams.

Pregnancy risk and treatment vary according to disease activity, organ involvement, kidney function, blood pressure, antibody profile, previous thrombosis or pregnancy complications, fetal findings, gestational age, medication exposure and other individual factors. A test result, symptom, scan finding or medicine discussed on this page should not be interpreted in isolation.

Do not start, stop, delay or change hydroxychloroquine, corticosteroids, immunosuppressive medicines, aspirin, heparin, another anticoagulant, blood-pressure treatment, supplements or any other prescribed therapy because of information on this page. Abrupt withdrawal or unsupervised substitution may cause lupus flare, thrombosis, bleeding, organ deterioration or pregnancy complications.

Seek urgent medical or maternity assessment for reduced or absent fetal movements, vaginal bleeding, fluid leakage, severe headache, visual disturbance, upper-abdominal pain, chest pain, significant breathlessness, fainting, one-sided leg swelling, seizure, new neurological symptoms, fever, markedly reduced urine output, severe hypertension symptoms, heavy postpartum bleeding, thoughts of self-harm or harming the baby, or feeling seriously unwell. Medical evidence and recommendations change; decisions must follow the current guidance, local resources and the judgement of the clinicians responsible for the mother and baby.

Evidence Base

Society for Maternal-Fetal Medicine. Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. American Journal of Obstetrics & Gynecology. 2023. Reaffirmed 2025. Endorsed by the American College of Obstetricians and Gynecologists. Official SMFM guidance
Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology. 2020;72(4):529–556. Official ACR guideline page
Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2017;76(3):476–485. Full text
American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics & Gynecology. 2020;135(6):e237–e260. Official ACOG guidance
Kidney Disease: Improving Global Outcomes Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney International. 2024;105(Suppl 1S):S1–S69. Official KDIGO guideline
Rüegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the Rheumatic Diseases. 2025;84(6):910–926. DOI and full text
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases. 2019;78(10):1296–1304. Full text
Izmirly P, Kim M, Friedman DM, et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology. 2020;76(3):292–302. Full text
Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis & Rheumatism. 2001;44(8):1832–1835. PubMed
Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis & Rheumatism. 2009;60(10):3091–3097. Full text
Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. The Journal of Pediatrics. 2003;142(6):678–683. PubMed
Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Annals of the Rheumatic Diseases. 2023;82(10):1258–1270. Full text
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases. 2024;83(1):15–29. Full text
Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. Journal of the American College of Cardiology. 1998;31(7):1658–1666. PubMed
Cuneo BF, Moon-Grady AJ, Sonesson SE, et al. Heart sounds at home: feasibility of an ambulatory fetal heart-rhythm surveillance program for anti-SSA-positive pregnancies. Journal of Perinatology. 2017;37:226–230. DOI